

---

# Index

References in *italics* refer to tables and figures.

2CMenB vaccine 342–3  
*see also* meningococcal vaccines

2-phenoxyethanol 29, 189

4CMenB vaccine 342–3  
*see also* meningococcal vaccines

23PPV vaccine 414  
contraindications and precautions 428  
dosage and administration 419–20, 569, 571  
efficacy and effectiveness 418–19  
expected responses and adverse events 429  
not funded but recommended 426  
recommended immunisation schedule 420–1, 422–3, 424, 425, 427  
special groups 6, 57, 116, 118, 121, 124–5, 130–1, 133–7, 139–42  
variations from vaccine data sheets 430  
*see also* pneumococcal vaccines

abdominal cramps 79

abdominal discomfort 186

abdominal pain 75, 78, 206

abortions, spontaneous 362

abscesses 529

abscesses at injection site 34, 64, 510

acellular pertussis vaccines 380, 381–2, 386, 388, 388, 579

*see also* DTaP vaccine; DTaP-IPV vaccine; Tdap vaccine

aching legs 655

acquired immune deficiency *see*  
secondary immune deficiencies

acquired immunodeficiency syndrome (AIDS) 569

Act-HIB vaccine 4, 175

*see also* Hib vaccines

acute febrile illness 92, 186, 197, 320

*see also* fever

acute flaccid paralysis (AFP) 34, 442, 449

acute gastroenteritis *see* gastroenteritis  
acute hepatitis B infection 206, 209–10, 223–5

acute illness 92

acute lymphoblastic leukaemia 549

acute myocardial infarct 287

acute otitis media (AOM) 407, 408, 417

acyclovir 545, 549, 554, 555

Adacel Polio vaccine 159, 380, 443, 501  
*see also* Tdap-IPV vaccine

Adacel vaccine *see* Tdap vaccine

adalimumab 120, 121, 468, 527

adaptive immune response 16–17, 19–20, 19

adenitis 528

adenopathy 529

adjuvanted vaccines 284

adjuvants 29, 103, 158, 190, 284, 297, 444, 500, 658

administration of vaccines 622

catch-up programmes *see* catch-up programmes

concurrent *see under* spacing of doses

contraindications and precautions  
*see* contraindications and precautions

inadequate vaccination records 54–5  
post-vaccination 48, 80

advice 74

anaphylaxis and emergency

management *see* anaphylaxis

disposal of needles, syringes and vaccine vials 664–5

documentation and insurance 83–4

expected responses *see* expected responses

fever and pain management 76–7

preparation 59–60, 60–1, 657–8

liquid preparation 658–9

multi-dose vials 663

powder/pellet vaccines 659–61

prefilled syringes 660–1

rotavirus vaccines 662

- presentation 657
- pre-vaccination 40, 80
  - conditions that are not contraindications *see under* contraindications and precautions
  - minimising pain and distress at time of vaccination 59
  - preparing for administration 59–60, 60–1, 657–63
  - screening and actions to take 48, 48–51
  - spacing of doses *see* spacing of doses
  - who can administer a vaccine *see* authorisation of vaccinators *see also* injections; vaccinators
- adolescents 242, 258, 351, 387, 392, 545
- catch-up programmes *see under* catch-up programmes
- injections 63, 64, 71–2, 77, 257
- not funded but recommended 348, 349–50, 350, 546
- recommendations and immunisation schedule 115, 216, 253–5, 318, 343, 345–7
- adrenal insufficiency 121, 570
- adrenaline 78, 80–2, 295, 638, 655
- ADT Booster vaccine *see* Td vaccine
- adults 79, 285–7, 387, 466, 545
  - catch-up programmes *see under* catch-up programmes
  - injections 63, 64, 71–2
  - not funded but recommended 56–8, 115, 164, 255–6, 293, 546
  - public health measures 392, 393–4
  - recommendations and immunisation schedule 55, 55, 56–8, 147–9, 193, 505
    - diphtheria vaccines 55, 163–4
    - hepatitis B vaccines 56, 216, 222–3, 222
    - Hib vaccines 56, 183
    - influenza vaccines 56, 289
    - meningococcal vaccines 57, 345–6, 349, 355
    - pneumococcal vaccines 57, 425
- adverse events following immunisation (AEFI) 90, 93, 96, 622–3
  - anaphylaxis *see* anaphylaxis
  - IG 655–6
  - previous dose reactions *see* previous dose reactions
- reporting process
  - CARM assessment of causality 35
  - notifying CARM 90, 529
  - safety monitoring system 30, 98
  - seriousness of 34–5
  - spontaneous reporting 31
    - advantages and limitations 36–7
    - notifying CARM 32–5, 34
    - understanding vaccine safety 37–8
    - what Medsafe does with information 36
- vaccines
  - BCG vaccine 528–9, 528
  - diphtheria vaccines 166
  - hepatitis A vaccines 198
  - hepatitis B vaccines 228–9
  - Hib vaccines 180
  - HPV vaccines 257
  - influenza vaccines 296–7
  - meningococcal vaccines 342, 351–2
  - MMR vaccines *see under* MMR vaccines
  - pertussis vaccines 386–8, 388
  - pneumococcal vaccines 427, 428–9
  - polio vaccines 448
  - rotavirus vaccines 34, 469–70
  - tetanus vaccines 34, 510–11
  - varicella vaccines 549–50, 553
  - zoster vaccines 570
    - see also* expected responses
- AFP (acute flaccid paralysis) 34, 442, 449
- African peoples 457, 519
- age 90, 213, 284, 387, 528, 528
- chronological age 91, 114, 218
- distribution 173, 379
  - HPV 239–42, 245, 246
  - meningococcal disease 337–8, 339
  - pneumococcal disease 409, 410, 411
  - rotavirus 457, 459, 466
  - tuberculosis 516–18, 520
  - vaccines 157, 188, 209, 278, 417, 566
  - zoster 537, 565–7, 566
- aged-care facilities *see* rest homes
- AIDS (acquired immunodeficiency syndrome) 569
- air bubbles, removal 61, 61
- airplane travellers 353
- albumin 29
- alcohol swabs 61, 663
- alcoholism 242, 244, 426

- allergic reactions 94, 99–100, 228, 295, 570, 654  
 anaphylaxis *see* anaphylaxis  
 eggs *see* egg allergy  
 gelatin *see* gelatin  
 vaccine components *see* vaccine components  
 yeast *see* yeast
- alternative injection sites 60, 64
- aluminium 103
- aluminium hydroxide or phosphate 29, 103, 158–9, 189–90, 341, 387, 414, 444, 500
- aluminium hydroxysulphate 212, 247–8
- American Academy of Pediatrics 676
- amino acids 189–90, 314, 540–1, 647
- anaesthetic 93
- anaesthetic cream 77
- anal cancers 236–7, 241–2, 244  
*see also* cancer
- anaphylaxis 34, 510  
 adrenaline *see* adrenaline  
 avoidance of 80  
 drug reactions 335  
 egg or chicken 51, 295, 299, 322, 328, 367, 489  
 emergency equipment and management 77, 80–3, 81, 82, 295, 299, 638  
 IG 654–6  
 reaction to previous dose *see under* previous dose reactions  
 risk of 228, 388  
 signs and symptoms 78–9, 78  
   distinguishing from a faint 79  
   distinguishing from HHE 79–80  
 vaccine components *see under* vaccine components
- angioedema 78
- animal exposure 526
- animals, individuals who work with 148
- anorexia 186, 206, 387, 517, 536
- antenatal screening 120  
 hepatitis B 211, 218–19, 224  
 rubella 487, 492–3  
 tuberculosis 524, 527
- antibiotics 94, 167, 247–8, 298–9  
 meningococcal disease 335, 335, 337, 352–4  
 pertussis 390–4, 392
- anti-D IG (Rhesus) 488, 646
- anti-immunisation views 96–7
- antimicrobial prophylaxis 166–7, 181–2, 390–4, 392, 429
- antimicrobial resistance 412–13
- antipyretic analgesics 77
- antiretroviral therapy 133, 248
- antiviral drugs 132, 213, 220–1, 298–9
- anxiety 37, 60, 77–8
- apnoeas 48, 115, 374–5
- appetite, loss of 75, 197, 428
- armed forces 148, 193, 546
- arthralgia 229, 335, 480–1
- arthritis 172, 362, 480–1, 490
- Arthus reactions 511
- artificially acquired immunity 20
- ASO<sub>3</sub> and ASO<sub>4</sub> endotoxins 29
- aseptic meningitis *see* meningitis
- Asian peoples 188, 210, 221, 224, 379, 519
- aspirin 8, 274, 291, 548
- asplenic children and adults 93, 116, 119, 121, 123, 138–43, 140–3  
 diphtheria vaccines 164–5  
 hepatitis B vaccines 223  
 Hib vaccines 7, 56, 93, 177–8, 179, 183  
 influenza vaccines 8, 93, 291  
 meningococcal vaccines 9, 57, 93, 336, 348  
 pertussis vaccines 9, 57, 384–5  
 pneumococcal vaccines 10, 57, 93, 422, 424–5  
 polio vaccines 446  
 varicella vaccines 93
- Association of Paediatric Anaesthetists of Great Britain and Ireland 93
- asthma 8–9, 94, 99–100, 291–2, 417, 422
- at-risk individuals *see* high-risk groups
- Attenuvax vaccine 314  
*see also* measles vaccines; MMR vaccines
- Australian Technical Advisory Group on Immunisation 470
- authorisation of vaccinators 39–40  
 authorised vaccinators *see* authorised vaccinators  
 authority 629–31  
 BCG endorsed vaccinators *see* BCG endorsed vaccinators  
 delivering local immunisation programme 638–42  
 new to health district 637

- pharmacist vaccinators *see* pharmacist vaccinators
- process 631–2
- process when status has not been renewed or achieved 634–5
  - less than five years 635–6
  - more than five years 636–7
- renewal process 633–4
- resuscitation requirements 637–8
- authorised vaccinators
  - authorisation of 629–37
  - BCG endorsed *see* BCG endorsed vaccinators
  - delivering local immunisation programme 638–42
  - pharmacist *see* pharmacist vaccinators
  - resuscitation requirements 637–8
- autism 99, 323
- autoimmune conditions or disease 8, 102, 128–9, 129, 249, 257, 291, 653, 655
- Avaxim vaccine 190, 195
  - see also* hepatitis A vaccines
- avian influenza virus 273, 280
- azathioprine 128, 570
- azithromycin 391–2
  
- B lymphocyte deficiency *see* humoral immune deficiency
- babies *see* infants
- Bacillus Calmette-Guérin (BCG) Vaccinator Endorsement* 633
- Bacillus Calmette-Guérin vaccine see* BCG vaccine
- background incident rates 38
- bacteraemia 138, 407, 418
- bacterial skin infections 537
- basic reproduction number ( $R_0$ ) 22, 23, 251, 310
- BCG endorsed vaccinators
  - additional endorsement process 632–3
  - injections 63, 65, 68–9
  - role and responsibility 522, 525
- BCG vaccine 91, 519–20
  - contraindications and precautions 124–6, 321, 526–8
  - dosage and administration 53, 63, 65, 68–9, 68, 69, 464, 522–3, 543, 657
  - efficacy and effectiveness 520–1
  - endorsed BCG vaccinators 65, 522
  - expected responses and adverse events 528–9, 528
  - history of schedule 576, 596
  - recommended immunisation schedule 523–6, 667
  - special groups *see under* special groups
  - transport, storage and handling 521–2
  - variations from vaccine data sheets 531
- BCG vaccine SSI 520
- behavioural problems 481
- Bell's palsy 570
- beta-propiolactone 283
- Bexsero vaccine 342
  - see also* meningococcal vaccines
- BGP Products Pty Ltd (Mylan EPD) 282
- biliary atresia 116
- bleeding disorders 51, 65
  - see also* thrombocytopenia
- blindness 481
  - see also* loss of vision
- blogs 105–6
  - see also* websites
- blood and body fluid exposures 208, 225, 666
- blood donations and donors 645–8, 656
- blood products 116, 217, 225, 467–8, 655
  - see also* IG
- blood transfusions 49, 321, 488, 652
- bloodstream infection 172
- boarding schools 347–8
  - see also* communal accommodation
- body fluids 208, 225, 666
- body piercers 149
- bone infection 517
- bone marrow conditions 569
- bone marrow transplants *see* haematopoietic stem cell transplant
- boosters 568
  - diphtheria vaccines *see under* diphtheria vaccines
  - hepatitis B vaccines *see under* hepatitis B vaccines
  - hepatitis B vaccines
  - Hib vaccines 131–2, 177
  - meningococcal vaccines *see under* meningococcal vaccines
  - meningococcal vaccines
  - pertussis vaccines *see under* pertussis vaccines
  - pertussis vaccines
  - pneumococcal vaccines *see under* pneumococcal vaccines
  - pneumococcal vaccines
  - polio vaccines 130–1, 445, 447

- tetanus vaccines *see under* tetanus vaccines  
 zoster vaccines 568
- Boostrix vaccine *see* Tdap vaccine  
 Boostrix-IPV vaccine 594  
 bovine calf serum 540, 567  
 bovine serum albumin 190, 443, 540  
 brachial plexus neuropathy 34, 510  
 bradycardia 79  
 brain damage 375  
 breastfeeding 114, 335, 353–4, 391, 454–5  
   refusing feeds 335  
   relieving measures 76  
   safe vaccines 95, 164, 179, 197, 223, 256, 292, 320, 350, 367, 384, 427, 446, 467, 488, 505, 526, 547  
   *see also* pregnancy  
 breath-holding spells 77, 78  
 bronchiectasis 292  
 bronchiolitis 274, 310  
 bronchitis 172, 175, 274  
 bronchodilators 83  
 bronchospasm 78, 83  
 buttock as injection site 64
- calcium chloride dihydrate 282  
 cancer 8, 130–1, 291, 417, 537, 565  
   HPV 236–7, 237, 240–4, 244, 250, 258–9  
   *see also* anal cancers; cervical cancer; oropharyngeal cancers  
 cardiac disease 9, 274, 291, 422  
 cardiac malformations 481  
 cardiopulmonary diseases 287  
 cardiopulmonary resuscitation 82, 631, 637–8  
 cardiorespiratory disorders 286  
 cardiovascular disease 8, 291, 570  
 carers 147, 318, 524, 667  
 CARM reporting 622  
   adverse events 31–8, 34, 90, 529  
   anaphylaxis reactions 83  
   HPV and pregnancy 256  
   serious reactions 80  
 cataracts 481  
 catch-up programmes 541–2, 599  
   adolescents 221–2, 317–18, 344, 365–6, 466, 485–6, 504, 600–6, 606, 610, 611  
   adults 55, 143–4, 164, 317–18, 365–6, 485–6, 504–5, 511, 611–12, 613  
   children 54–5, 115, 143–4, 163, 177, 221–2, 317–18, 365–6, 383, 394, 420, 466, 485–6, 504, 545, 600–6, 603, 606, 608, 609, 610  
   infants 600–6, 603, 607  
 cefotaxime 182, 337, 413  
 ceftriaxone 182, 337, 354  
 cellular immune deficiencies 569  
 cellulitis 172  
 Centers for Disease Control and Prevention (CDC) (US) 146, 569, 675, 678, 679  
 central nervous system symptoms 8, 131, 291, 311, 537  
 Centre for Adverse Reactions Monitoring (CARM) *see* CARM reporting  
 cerebellar ataxia 537, 548  
 cerebrospinal fluid leaks 9, 422, 426  
 cerebrovascular disease 8, 291, 570  
 cervical cancer 236–7, 239–43, 250, 251, 258–9  
   *see also* cancer  
 cervical disease 102  
 cervical screening programmes 258–9  
 cetrimonium bromide 282  
 chemicals, toxic 103  
 chemoprophylaxis 181–2, 353–4, 393–4  
   rifampicin *see* rifampicin  
   chemoprophylaxis  
 chemotherapy 56–8, 123, 130, 164–5  
   hepatitis B vaccines 56, 130, 223  
   Hib vaccines 7, 56, 178, 179  
   HPV vaccines 7, 56, 253–4  
   influenza vaccines 56, 127, 293  
   pertussis vaccines 9, 57, 130, 384–5  
   pneumococcal vaccines 10, 57, 130, 425  
   polio vaccines 57, 130, 446  
   tetanus vaccines 57, 130, 508–9  
   varicella vaccines 11, 58, 544, 548  
 chest pain 517, 655  
 chewing difficulties 498  
 chicken embryo 314  
 chicken protein 282  
 chickenpox *see* varicella zoster virus  
 child-bearing aged women 221, 277, 321, 328, 427, 501, 546  
   rubella 55, 319, 485, 487, 612  
 childbirth, difficult 91

children 47, 62–4, 78, 195, 199, 354  
   catch-up programmes *see under*  
   catch-up programmes  
   contraindications and precautions  
     294, 488, 569  
   not funded but recommended  
     349–50, 350  
   public health measures 392, 393  
   recommendations and immunisation  
     schedule 141–2, 445–6, 503–4, 599  
     hepatitis B vaccines 216, 217–18,  
       217  
     influenza vaccines 142, 285–6,  
       288–9, 289, 292–3  
     meningococcal vaccines 141–2,  
       345–6, 349–50, 355  
     MMR vaccines 317, 365–6, 485–6  
     pertussis vaccines 115, 383–4  
     pneumococcal vaccines 141–2,  
       420–1, 422–3, 424, 425  
     varicella vaccines 142, 545  
   *see also* immigrants; infants;  
   neonates; older children; young  
   children  
 chills 273, 343, 427, 517  
 Chinese peoples 210  
 Chiron/Novartis 342  
 chronic cardiac disease 426  
 chronic conditions 93, 213, 225, 292,  
   409, 426  
 chronic fatigue syndrome (CFS) 102–3,  
   228  
 chronic gastrointestinal diseases 467,  
   471  
 chronic granulomatous disease 126  
 chronic hepatitis B infection *see under*  
   hepatitis B virus  
 chronic kidney disease (CKD) 116, 131  
 chronic liver disease 7, 10, 58, 186–7,  
   193–4, 204, 225, 426, 544  
 chronic lung disease 115, 116, 121, 143,  
   292  
 chronic pulmonary disease 9, 287, 422,  
   426  
 chronic renal failure 8, 126, 225, 291,  
   426  
 chronic respiratory disorders 8, 291,  
   292, 393  
 chronic septic arthritis 335  
 chronological age 91, 114, 218  
 ciprofloxacin 337, 354  
 cirrhosis 204, 207, 208, 213  
 citric acid 520  
 clarithromycin 392  
 clay coloured stools 206  
 clinical history of infection 11, 52, 58,  
   317, 486, 544–6  
   *see also* wild-type virus  
 clonal deletion 27  
 clonic seizure activity 79  
 close contacts *see* household and close  
   contacts  
 coagulation disorders 655  
 cochlear implants 7–10, 56–7, 121, 179,  
   291, 422, 424–5  
 Code of Health and Disability Services  
   Consumers' Rights 42–3, 47, 616  
 cold chain management 40, 41  
 collapse 78, 116  
 coma 335  
 common vaccine response *see* expected  
   responses  
 communal accommodation 57, 150,  
   336, 347–8, 353  
*Communicable Disease Control*  
*Manual 2012* 13  
 communities, semi-closed 336  
   *see also* communal accommodation  
 community gatherings, exclusion 167,  
   326–7, 393–4  
 community immunity *see* herd  
   immunity  
 community outbreaks 195, 199  
   *see also* outbreaks  
 co-morbid conditions 275, 287, 293,  
   385  
 complement deficiency 9–10, 57, 122–3,  
   125, 348, 425  
 complex regional pain syndrome  
   (CRPS) 102–3  
 components of vaccines *see* vaccine  
   components  
 compulsorily detained patients within  
   DHB hospital 8, 291  
 confidentiality 620–1  
 congenital defects *see* fetal  
   abnormalities or damage  
 congenital diabetes 121  
 congenital heart disease 8, 116, 138,  
   291, 393  
 congenital malformation of the  
   gastrointestinal tract 467  
 congenital rubella syndrome *see* CRS

- congenital T-cell immune deficiency syndrome 545
- congenital varicella syndrome (CVS) 537, 539, 556, 556
- congestive heart failure 8, 291
- conjugate vaccines 27–8, 90, 101
- Hib vaccines 90, 101, 175
- meningococcal vaccines 27, 125, 340–1, 346–7
- pneumococcal vaccines 27–8, 90, 101, 125, 290, 296, 412–13, 417–18, 428–9, 580
- conjunctivitis 273, 310, 324
- contaminated linen 665
- contraception 240, 242, 259, 354
- contraindications and precautions 51, 90, 94, 622
- acute febrile illness 197, 320
- adrenaline 81
- allergies *see* allergic reactions
- anaphylaxis *see* anaphylaxis
- conditions that are not 52, 91–5, 114, 295, 322, 367, 388, 427, 471, 489, 511, 570
- HIV infection 321, 527, 569
- IG 49, 321, 654–5
- immunosuppression *see under* immunosuppression
- operations and elective surgery 93
- pregnancy *see under* pregnancy
- reaction to previous dose *see* previous dose reactions
- receipt of another vaccine, blood or IG *see under* spacing of doses
- vaccines
- BCG vaccine 124–6, 321, 526–8
- diphtheria vaccines 165
- hepatitis A vaccines 197
- hepatitis B vaccines 228
- Hib vaccines 180
- HPV vaccines 256
- influenza vaccines *see under* influenza vaccines
- live vaccines *see under* live vaccines
- meningococcal vaccines 350
- MMR vaccines *see under* MMR vaccines
- MMRV vaccines 545, 550
- pertussis vaccines *see under* pertussis vaccines
- pneumococcal vaccines 427–8
- polio vaccines 446, 447–8
- rotavirus vaccines *see under* rotavirus vaccines
- tetanus vaccines 509–10
- varicella vaccines 125, 547–8, 552
- zoster vaccines 569–70
- corneal ulceration 310
- correctional institutions and staff 147–8, 150, 217, 225, 336, 347–8, 546
- cortical atrophy 556
- corticosteroid therapy 9, 127–9, 128, 422, 527, 570
- coryza 310, 324
- cot death 100, 386
- coughing 273–4, 324, 374–5, 390, 393, 517
- counselling workers 147
- CPR 82, 631, 637–8
- cramps 79, 498
- croup 274, 310
- crowding 337–8, 363, 455
- CRS 480–2, 485, 487, 490–1
- crying 351, 387, 470
- CSL Behring Australia 551, 645, 647–8
- culture medium 460
- cyanosis 9, 79, 374, 422
- cystic fibrosis 121, 292, 417
- cytomegalovirus immunoglobulin 653
- dark urine 186, 206
- deafness 481
- death *see* mortality
- defective cell-mediated immunity 311
- dehydration 454–5
- delayed hypersensitivity *see* hypersensitivity
- delayed immunisation 92, 101, 197, 219, 256, 320
- BCG vaccine 120, 121, 525, 527–8
- pertussis vaccines 101, 386, 395
- deltoid injection sites 62–4, 69–73, 70, 71, 72, 82
- demyelination 155
- dermatitis 321
- deteriorating renal function 10
- deterioration 116
- development disorders 217, 225, 556
- DHBs 11, 86, 280, 291, 525, 530, 655
- compulsorily detained patients within 8, 291

- diabetes 228, 565
  - influenza disease and vaccines 8, 121, 281, 287, 291–2
  - pneumococcal vaccines 10, 121, 417, 422, 426
- dialysis 7, 56, 132, 216, 218, 221–2
  - see also* haemodialysis; renal dialysis
- diarrhoea 75, 228, 273, 310, 448
  - rotavirus 120, 454–5, 460, 461, 462, 469, 471
- difficult births 91
- DiGeorge syndrome 116, 125
- diphtheria
  - bacteriology 154
  - clinical features 154–5
  - epidemiology 155–7, 156
  - incubation period 154
  - key information 153
  - public health measures 166–7
- diphtheria toxoid 27, 158–9
- diphtheria vaccines 26, 158–9
  - boosters 130, 160–4, 167, 612
  - contraindications and precautions 165
  - dosage and administration 161
  - efficacy and effectiveness 157–8, 160–1
  - expected responses and adverse events 75, 166
  - history of schedule 575, 587
  - recommended immunisation schedule 162–4, 162
  - single-antigen vaccine 162, 504
  - special groups 130–1
  - transport, storage and handling 161
- dipotassium phosphate 520
- Director of Public Health 449
- Director-General of Health 39, 629–30, 638
- disability 539
- discomfort, abdominal 186
- discomfort at injection site 75, 166, 429, 510
- disease-modifying anti-rheumatic drugs
  - see* DMARDs
- disodium adipate 460
- disodium phosphate 159
- disposal of needles, syringes and vaccine vials 664–5
  - see also* needle-stick injuries
- distress 59
- District Health Boards *see* DHBs
- dizziness 78, 655
- DMARDs 120, 121, 129, 468, 527
- documentation and records 54–5, 83–6, 620–1, 643–4
- dormitories 353
  - see also* communal accommodation
- Down syndrome 8, 10, 121, 291, 422
- drinks and feeds, refusing 335
- drowsiness 75
- drug therapy 321
- drug users 150
  - hepatitis A vaccines 187, 195
  - hepatitis B vaccines 208, 217, 223, 224–5
- drugs 83, 120, 651
  - see also specific drugs*
- DTaP (diphtheria, tetanus, acellular pertussis) vaccines 75, 579
  - see also* acellular pertussis vaccines; pertussis vaccines
- DTaP-IPV (diphtheria, tetanus, acellular pertussis, inactivated poliovirus) vaccine 159, 380, 443, 501
  - catch-up programmes 601, 609–10
  - dosage and administration 161, 382, 428, 444–5, 503
  - expected responses and adverse events 387
  - recommended immunisation schedule 5, 162, 383–5, 445–7, 503–4
  - special groups 118, 133, 164–5, 384–5, 446–7, 508–9
  - variations from vaccine data sheets 394–5
  - see also* acellular pertussis vaccines; pertussis vaccines
- DTaP-IPV-HepB/Hib (diphtheria, tetanus, acellular pertussis, inactivated poliovirus, hepatitis B, Hib) vaccine 158–9, 175, 212, 380, 443, 501
  - catch-up programmes 601, 607–10
  - dosage and administration 161, 176, 215, 382, 428, 444–5, 503, 657, 659
  - efficacy and effectiveness 381
  - expected responses and adverse events 387
  - recommended immunisation schedule 5, 162, 177, 179, 217–18, 220, 383–5, 445, 503–4, 503
  - special groups 118, 133, 164–5, 179, 218, 223, 384–5, 446–7, 508–9



- transport, storage and handling 161, 176, 214, 382, 444, 502  
 variations from vaccine data sheets 394–5  
*see also* acellular pertussis vaccines; pertussis vaccines
- DTwP (diphtheria, tetanus, whole-cell pertussis) vaccine 576  
*see also* pertussis vaccines; whole-cell pertussis vaccines
- dyspnoea 78
- dysrhythmias 78–9, 81
- early childhood education services 187, 336, 465, 539  
 immunisation certificates and register 643–4  
 not funded but recommended 146, 193, 385, 546  
 occupational risks 146, 147, 455  
 public health measures 181–2, 199, 353, 389, 471  
 exclusion 167, 326–7, 368–9, 393–4, 491, 554
- economic status *see* socioeconomic status
- eczema 94, 527
- efficacy and effectiveness 104–5, 124–6, 133  
 BCG vaccine 520–1  
 diphtheria vaccines 157–8, 160–1  
 hepatitis A vaccines 190–1, 198  
 hepatitis B vaccines 101, 212–14  
 Hib vaccines 101, 175–6  
 HPV vaccines *see under* HPV vaccines  
 immunoglobulin 229  
 influenza vaccines 282–8, 285, 290  
 live vaccines 283–4  
 meningococcal vaccines 343–5  
 MMR vaccines *see under* MMR vaccines  
 MMRV vaccines 542  
 pertussis vaccines *see under* pertussis vaccines  
 pneumococcal vaccines 101, 415–19  
 polio vaccines 443–4  
 rotavirus vaccines 460–3, 461  
 tetanus vaccines 101, 382, 501–2  
 varicella vaccines 541–2, 545  
 zoster vaccines 567–8
- egg allergy 49, 51, 294–5, 299, 322, 328, 367, 489  
 egg protein 30, 49, 51, 282, 295, 322  
 elderly *see* older adults  
 elective surgery 93, 139  
 Eligibility Direction 12, 92, 599  
 emergency and essential service workers 148, 291, 293  
 employers 147, 192, 195, 293, 298  
 emulsifiers 29  
 emulsions 29, 284  
 encephalitis 310–11, 322, 362, 480–1, 537, 548, 570  
 encephalomyelitis 228  
 encephalopathy 34, 274, 395, 570  
 endocrine disorder 121  
 endotoxin 29  
 Engerix-B vaccine 212  
*see also* hepatitis B vaccines
- epidemics  
 hepatitis A 199  
 influenza 272, 274, 298  
 measles 311–13, 315, 320  
 meningococcal disease 336, 337, 339, 342, 347, 350  
 mumps 363  
 pertussis 375, 376–7  
 polio 441  
 rotavirus 455  
 rubella 481  
 varicella zoster virus 537  
*see also* outbreaks; pandemics
- epiglottitis 172
- epilepsy 93–4
- Epstein-Barr virus 102
- erythema 78, 228, 257, 429, 448, 655  
 erythema multiforme 180  
 erythromycin 166, 391–2  
 ESR 275, 408, 449, 674, 677  
*see also under* websites
- ethnicity  
 distribution 188, 338, 409, 457, 519  
 hepatitis B 209–10, 221, 224  
 HPV 242–3, 245  
 influenza 275–8, 281  
 pertussis 377, 379
- European Medicines Agency 252
- European or Other peoples 209–11, 242, 377, 379, 409, 519
- Evogam immunoglobulin 648, 650, 654  
*see also* IG

- exclusion of contacts 167, 326–7, 368–9  
 community gatherings, exclusion  
 167, 326–7, 393–4  
 early childhood education services  
*see under* early childhood  
 education services  
 hospital settings 547, 553–4  
 schools *see under* schools  
 work *see* work, exclusion
- expected responses 74, 75  
 BCG vaccine 528  
 diphtheria vaccines 75, 166  
 hepatitis A vaccines 197  
 hepatitis B vaccines 75, 228  
 Hib vaccines 75, 180  
 HPV vaccines 75, 257  
 IG 655–6  
 influenza vaccines 75, 296–7  
 meningococcal vaccines 351–2  
 MMR vaccines *see under* MMR  
 vaccines  
 MMRV vaccines 550  
 pertussis vaccines 75, 386–7  
 pneumococcal vaccines 75, 428–9  
 polio vaccines 448  
 rotavirus vaccines 75, 469–70  
 tetanus vaccines 75, 510  
 varicella vaccines 75, 548–9  
 zoster vaccines 570  
*see also* adverse events following  
 immunisation
- eye complications 556, 564
- facial scarring 564
- failure to thrive 120, 517
- fainting 37, 75, 77–9, 79, 257
- false beliefs *see* questions and concerns
- family *see* household and close  
 contacts; parents/guardians
- fatality *see* mortality
- fatigue 343, 351, 387, 517
- febrile convulsions *see* febrile seizures;  
 fever
- febrile illness *see* fever
- febrile seizures 34, 342, 462  
 influenza vaccines 94, 296  
 MMR vaccines 94, 322, 550  
 pertussis vaccines 386, 388  
 pneumococcal vaccines 419, 427  
 varicella vaccines 94, 543, 550  
*see also* fever
- ferric ammonium citrate 520
- fetal abnormalities or damage 113, 292,  
 362, 446, 480, 493, 527, 547
- fetal loss 223
- fever 34, 48, 93, 351, 655–6  
 acute febrile illness *see* acute febrile  
 illness  
 relieving measures 76  
 vaccines and disease 75, 197, 387,  
 510, 517  
 hepatitis B 206, 228  
 Hib 75, 181  
 influenza 75, 273–4, 289–90,  
 292, 294, 296  
 meningococcal 335, 342  
 MMR 75, 310, 320, 322, 324, 362,  
 490  
 pneumococcal 75, 290, 296, 419,  
 427, 428  
 polio 440, 448  
 rotavirus 454, 469  
 varicella 75, 536, 549, 550  
*see also* febrile seizures
- Fitfortravel 679
- floppiness 335
- FluQuadri vaccine 282–3  
*see also* influenza vaccines
- flushing 78
- Fluvax vaccine 282, 294, 296  
*see also* influenza vaccines
- fontanelle, bulging 335
- food handlers 167
- formaldehyde 300, 103, 158–9, 190,  
 282–3, 443, 500
- fretfulness 387
- funded vaccines 4, 5, 6, 7–11, 117–19,  
 143, 599  
 BCG vaccine 10, 121, 524, 526, 667  
 diphtheria vaccines 10, 55, 158–9,  
 162–5  
 hepatitis A vaccines 7, 56, 133, 189,  
 192–3, 195–6  
 hepatitis B vaccines 7, 56, 132–3,  
 137, 211–13, 216–17, 218, 222–4  
 Hib vaccines 7, 56, 133, 138–9, 141–2,  
 175, 177–9  
 HPV vaccines 7, 55–6, 133, 136–7,  
 139–40, 247, 253–5, 254, 605, 612  
 influenza vaccines 8, 56, 95, 112,  
 120–1, 124, 127, 133–7, 139–40,  
 279, 282, 291, 292  
 meningococcal vaccines 9, 57, 133–7,  
 139–41, 341, 346, 348, 354

- MMR vaccines 8, 55, 57, 111–12, 114, 130, 135–7, 314, 317–20, 328, 363–6, 483, 485–8, 612
- pertussis vaccines 9, 57, 95, 113, 115, 139, 380, 383–5, 395, 612
- pneumococcal vaccines 9–10, 57, 121, 134–7, 139–42, 414, 420–1, 422–3, 424, 425, 425, 427
- polio vaccines 10, 55, 57, 443, 445–7
- rotavirus vaccines 460, 464
- tetanus vaccines 10, 55, 57, 133, 500–1, 503–5, 508–9, 511
- varicella vaccines 10–11, 58, 114, 120–1, 124, 130, 133, 135–7, 139–40, 142, 540, 544–5
- funeral workers 149
- Gardasil 9 vaccine *see* HPV9 vaccines
- Gardasil vaccine *see* HPV4 vaccines
- gastroenteritis 12, 454–7, 458, 461–2, 465, 467, 471
- gastrointestinal symptoms 387, 440
- gastrointestinal tract infection 517
- gazetting of BCG vaccinators *see* BCG endorsed vaccinators
- GBS 34, 180, 295–6, 352, 355, 510, 511
- gelatin 29, 30, 49, 540, 567, 569
- gender 209, 297, 441, 565
- HPV 239, 244–5, 246, 257, 259
- general/medical practitioners 39, 82, 93, 259, 324, 385, 493
- genetic factors 240
- genital warts 22, 102, 236, 240, 242, 245, 246, 250–1
- gentamicin 282
- Global Advisory Committee on Vaccine Safety 31, 103, 257
- Global Polio Eradication Initiative 441–2
- glycerol 520
- glycine 29, 159, 646, 648
- grizzliness 75
- GSK (GlaxoSmithKline) 29, 158–9, 175, 189–90, 212, 314, 363, 380, 443, 460, 483, 501, 540–1
- Guidance on Infectious Disease Management under the Health Act 1956* 12
- Guidelines for organisations storing vaccines and/or offering immunisation services 40, 615
- access of service 625–6
- achieves high immunisation coverage of its population 624
- links to primary health care and Well Child 623
- supports vaccinators and NIR administrators 624–5
- Guidelines for the management of tetanus-prone wounds* 507
- Guillain-Barré syndrome *see* GBS
- haematologists 552
- haematopoietic stem cell transplant (HSCT) 9, 57, 131, 164–5, 384–5, 508–9
- hepatitis B vaccines 7, 56, 131, 216, 223, 225
- Hib vaccines 7, 56, 131, 179
- meningococcal vaccines 9, 57, 131, 348
- pneumococcal vaccines 9–10, 57, 131, 422, 424–5, 426
- polio vaccines 131, 446
- varicella vaccines 11, 58, 131, 544, 548, 550
- haemodialysis 213, 225
- haemoglobinopathies 8, 121, 291
- haemolysis 656
- haemophilia 217, 225
- Haemophilus influenzae* type b (Hib) disease *see* Hib disease
- haemoptysis 517
- hair loss 228
- Hajj pilgrimage 347–8
- HAV *see* hepatitis A virus
- HAV-HepB vaccine 118, 190, 196, 212, 227
- Havrix/Havrix Junior vaccine 117–18, 189, 195
- see also* hepatitis A vaccines
- hay fever 52, 94
- HBeAg negative 205, 207, 221
- HBeAg positive 205, 207, 213, 221
- HBIG 91, 218–20, 229–30, 230, 523, 646, 652
- HBsAg positive mothers *see under* HBsAg positive
- Hb-OC Hib vaccine 174
- see also* Hib vaccines
- HBsAg positive 205–8
- individuals 216–17, 224–5
- mothers 7, 89, 91, 115, 119, 207–8, 216, 218–21, 220, 224, 229–30, 653

- HBV *see* hepatitis B virus
- HBvaxPRO vaccine 190, 196, 212, 223  
 catch-up programmes 604  
 HBsAg mothers 91, 219  
 special groups 117–18, 132, 137  
*see also* hepatitis B vaccines
- headache 75, 197, 228, 273, 362, 387, 440  
 HPV vaccines 75, 257  
 meningococcal vaccines 343, 351
- Health (Immunisation) Regulations 1995 643
- Health (Infectious and Notifiable Diseases) Regulations 2016 12
- Health (Protection) Amendment Act 2016 530
- Health Act 1956 12, 44, 85
- Health and Disability Commissioner 43, 47
- Health and Disability Commissioner Act 1994 616
- Health and Disability Commissioner (Code of Health and Disability Services Consumers' Rights) Regulations 1996 616
- Health and Disability Services Eligibility Direction 2011* 12, 92, 599
- health care personnel 30, 83, 85, 167, 353  
 AEFI reporting process 33  
 indemnity insurance 84  
 occupational risks 146, 147–9, 193, 224, 447, 526, 546–7  
 influenza and influenza vaccines 280, 281, 288, 291, 293, 294  
 MMR vaccines 318, 368  
 pertussis vaccines 385, 389–90, 394  
 role and responsibility 42–6, 96–7, 256, 470, 524, 654  
*see also* general/medical practitioners; vaccinators
- health care settings 336, 393
- health information 43–4, 85, 620–1, 644
- Health Information Privacy Code 1994 43–4, 85
- Health Practitioners Competence Assurance Act 2003 43
- Health Promotion Agency (HPA) 675
- Health Protection Agency 326
- HealthEd 674  
*see also under* websites
- heart disease 274, 291, 422
- heart failure 155
- hepatitis 310
- hepatitis A and B combination vaccines *see* HAV-HepB vaccine
- hepatitis A and typhoid vaccines 190
- hepatitis A vaccines 189–90  
 contraindications and precautions 197  
 dosage and administration 191–2  
 efficacy and effectiveness 190–1, 198  
 expected responses and adverse events 197–8  
 recommendations and immunisation schedule 56, 192–6, 193, 195–6  
 special groups 56, 117–18, 133  
 transport, storage and handling 191
- hepatitis A virus (HAV)  
 clinical features 186  
 epidemiology 187–8, 189  
 incubation period 186, 191  
 key information 185  
 public health measures 198–9, 649, 652  
 virology 186
- hepatitis B (HepB) vaccines 6, 26, 212  
 boosters 130, 213–14, 221–2, 227  
 catch-up programmes 604, 610  
 contraindications and precautions 228  
 dosage and administration 192, 215  
 efficacy and effectiveness 101, 212–14  
 expected responses and adverse events 75, 228–9  
 HBsAg positive *see* HBsAg positive history of schedule 577, 588–9  
 monovalent hepatitis B vaccine 212, 604  
 recommended immunisation schedule 56, 216–21, 216–17, 222  
 special groups *see under* special groups  
 transport, storage and handling 214
- hepatitis B immunoglobulin *see* HBIG
- hepatitis B virus (HBV)  
 acute infection 206, 209–10, 223–5  
 carriers *see* HBeAg negative; HBeAg positive; HBsAg positive  
 chronic state 7, 145, 193–4, 206–7, 224, 229–30, 523

- epidemiology 208–11, 214
  - screening 224–5
  - clinical features 204–8
  - epidemiology 208–11
  - incubation period 206
  - key information 203–4
  - public health measures 229–30, 230, 638
  - routes of transmission 207–8
  - serological testing *see under* serological tests
  - virology 204
- hepatitis C infection 7, 56, 193–4, 216
- Hepatitis Foundation of New Zealand 224
- hepatocellular carcinoma 204, 207, 208, 211, 214, 224
- Hepatitis vaccine (hepatitis A and typhoid vaccines) 190, 196
- HepB vaccines *see* hepatitis B vaccines
- herd immunity 21–2, 23, 175, 191
  - diphtheria 23, 156, 160
  - HPV 245, 251
  - influenza 23, 288
  - meningococcal disease 340, 344
  - MMR 23
  - no effects 23, 499, 521
  - pertussis 23
  - pneumococcal disease 407–8, 412
  - polio 23
  - rotavirus 456, 462–3, 468
  - varicella 23, 538, 542
- herpes zoster (HZ) *see* zoster
- herpes zoster vaccine (HZV) *see* zoster vaccines
- Hib disease 178
  - bacteriology 172
  - clinical features 172
  - epidemiology 173–4, 174
  - incubation period 172
  - key information 171
  - public health measures 181–2
- Hib vaccines 4, 174–5
  - boosters 131–2, 177
  - catch-up programmes 601
  - contraindications and precautions 180
  - dosage and administration 176, 543, 657, 659
  - efficacy and effectiveness 101, 175–6
  - expected responses and adverse events 75, 180
  - history of schedule 578, 587–8
  - recommended immunisation
    - schedule 5, 56, 90, 177–9, 177
  - special groups *see under* special groups
  - transport, storage and handling 176
  - variations from vaccine data sheets 183
- Hiberix vaccine 4, 5, 141–2, 175–9, 183
  - see also* Hib vaccines
- Hib-PRP-T vaccines 175–80, 183
  - see also* Hib vaccines
- higher deprivation *see* household deprivation; socioeconomic status
- high-incidence countries for TB 524, 667, 668–71
- high-risk groups 28, 85, 143, 192, 194–5
  - BCG vaccine 521, 524, 526, 667
  - hepatitis B vaccines 225, 225, 226, 227
  - influenza vaccines 288, 290, 292, 293, 299
  - meningococcal vaccines 341, 346–7, 349, 355
  - pertussis vaccines 390, 393–4
  - pneumococcal vaccines 9, 420, 421, 422–3, 424, 425–6, 429
  - varicella vaccines 550, 553–4
  - see also* special groups
- HIV infection 123, 133–4, 134–7, 517–18, 665–6
  - BCG vaccine 120, 527, 531
  - contraindications and precautions 321, 527, 569
  - hepatitis A vaccines 186
  - hepatitis B vaccines 7, 56, 213, 216, 222, 225
  - Hib vaccines 178
  - HPV vaccines 7, 56, 133, 239, 242, 248, 253–4
  - influenza vaccines 8, 120, 291
  - meningococcal vaccines 9, 57, 120, 348
  - MMR vaccines 133, 319–21, 366–7, 488–9
  - pneumococcal vaccines 9–10, 57, 120, 417, 422, 424–5
  - rotavirus vaccines 133, 455, 468
  - varicella vaccines 11, 58, 120, 537, 544, 548
  - zoster vaccines 565, 569
- hives 295

- hoarseness 78
- Hodgkin's disease 178, 426, 527
- homeless 291
- homosexual men *see* men who have sex with men
- hospital contact 551
  - exclusion 547, 553–4
  - see also* household and close contacts
- hospital workers 199, 319, 366, 488, 553–4
- hospitalisation 34, 77, 82–3, 91, 188, 335, 339, 364, 466
  - infants 466, 551
  - influenza 275–8, 277, 278, 286–7, 295
  - pertussis 100–1, 376–80, 378, 379
  - pneumococcal disease 100–1, 408, 412, 415–16
  - rotavirus 455–7, 458, 459, 460–1, 462, 470
  - varicella zoster virus 10, 537–9, 541–2, 553–4
  - zoster 566, 566
- hostel accommodation 57, 150, 336, 347–8, 353
- household and close contacts 57, 122–4, 166–7, 181–2, 429
  - hepatitis A 7, 56, 187, 193, 198–9
  - hepatitis B 7, 56, 208, 216–17, 224–5, 230
  - influenza 115, 130, 293, 612
  - meningococcal disease 9, 57, 336, 348, 352–4
  - MMR 123, 130, 315, 319, 325–7, 366, 368–9, 488, 491
  - pertussis 113–15, 385, 389, 393–4, 612
  - polio 442, 446–7
  - rotavirus 123, 468
  - tuberculosis 10, 145, 521, 523–5, 530, 667
  - varicella 11, 58, 119, 123–4, 130, 133, 538, 544–5, 547, 549, 551, 553
  - zoster 565, 569
  - see also* exclusion of contacts; occupational risks; sexual partners
- household crowding 337–8, 363, 455
- household deprivation 242, 277, 379–80, 412, 457
  - see also* socioeconomic status
- HPV
  - clinical features 238–40
  - epidemiology 22, 241–6, 244, 246
  - key information 235–6
  - prevention measures 258–9
  - virology and the causal link to cancer 236, 237
  - see also* cervical cancer; genital warts
- HPV vaccines 12, 26, 247, 247–8, 252, 258
  - catch-up programmes 605, 611–12, 613
  - contraindications and precautions 256
  - dosage and administration 252–3, 255
  - efficacy and effectiveness 101, 102–3, 248–52, 256, 259
  - expected responses and adverse events 75, 257
  - history of schedule 580, 589–90
  - interchangeability of 253, 259, 612
  - recommendations and immunisation schedule 5, 55, 56, 252, 253–6, 254, 612
  - special groups *see under* special groups
  - transport, storage and handling 252
  - variations from vaccine data sheets 259
- HPV4 vaccine 247–8
  - efficacy and effectiveness 102–3, 248–52
  - expected responses and adverse events 257
  - interchangeability of 254, 259, 605–6, 611–12
  - not funded but recommended 255–6
  - special groups 58, 119, 136–7
  - see also* HPV vaccines
- HPV9 vaccine 5, 247, 252
  - catch-up programmes 612
  - efficacy and effectiveness 249–50
  - expected responses and adverse events 257
  - not funded vaccines 255–6
  - special groups 118, 136–7
  - variations from vaccine data sheets 259
  - see also* HPV vaccines
- HSCT transplants *see* haematopoietic stem cell transplant
- human albumin 540
- human normal immunoglobulin 491–3, 523, 645
  - see also* Evogam immunoglobulin; IG; IVIG; Normal Immunoglobulin-VF

- human papillomavirus *see* HPV  
 Humira 120, 468  
 humoral immune deficiency 122, 124–5, 545, 649  
 hydration 76, 656  
 hydrocortisone 81, 83  
 hydrolysed porcine gelatin 567  
 hypersensitivity 34, 180, 509–11, 655  
   eggs 299  
   previous dose or vaccine compound 427, 509, 527, 547, 569  
   yeast 256  
 hypertension 81  
 hypogammaglobulinaemia 527, 655  
 hyporesponsiveness to vaccine 27–8, 227–8  
 hypotension 78–9, 656  
 hypotonic-hyporesponsive episode 34, 79–80, 388  
 HZ *see* zoster  
 HZV *see* zoster vaccines
- ibuprofen 76, 77  
 IG 20, 133, 645  
   accessing or contacting NZBS 648–9  
   contraindications and precautions 49, 321, 654–5  
   dosage and administration 198, 326, 650–1  
   receipt of another vaccine, blood or IG *see under* spacing of doses  
   duration of effect 654  
   efficacy and effectiveness 229  
   expected responses and adverse events 655–6  
   immune response and 229, 656  
   indications for use 194  
   immune deficiencies *see under* immunosuppression  
   post-exposure prophylaxis *see* post-exposure prophylaxis  
   pre-exposure prophylaxis 649  
 preparations available in NZ 645  
   human normal for intramuscular use *see* Normal Immunoglobulin-VF  
   human normal for intravenous use *see* IVIG  
   human normal for subcutaneous use 648, 650, 654  
 specific immunoglobulin 646  
   anti-D Rhesus 488, 646  
   hepatitis B *see* HBIG  
   rabies 645–6, 652  
   tetanus 506–7, 646–7, 652  
   varicella zoster *see* ZIG  
   zoster *see* ZIG
- illicit drug users *see* drug users  
 illness 48, 92, 94, 467  
 IMAC *see* Immunisation Advisory Centre
- immigrants 90, 92, 145, 538  
   hepatitis B 145, 217, 221, 225  
   MMR 318, 486  
   tuberculosis 144–5, 519, 523, 526  
 immigration/refugee centres 148  
 immune deficiency *see* immunosuppression  
 immune dysfunction *see* immunosuppression  
 immune response 16–17, 95, 206, 520–1, 530  
   enhanced 29, 284, 381, 537, 541  
   IG and 229, 656  
   impairment of 53, 93, 131–2, 213, 346, 419, 568  
   non-responders to vaccination *see* vaccine failure  
   reduced or inadequate 118, 133, 221, 428, 564  
 immune system 15, 19, 28, 29  
   boost by other means 92  
   overloading or overwhelming 100–1  
 immune thrombocytopenic purpura (ITP) *see* thrombocytopenia
- immunisation  
   concerns *see* questions and concerns  
   history of 575–80, 581–6, 587–97  
   immunity and 15–21  
   information on *see* immunisation information  
   practices  
     catch-up programmes *see* catch-up programmes  
     inadequate vaccination records *see* interrupted immunisation  
     safe processes *see* safe immunisation processes  
     spacing of doses *see* spacing of doses  
 Immunisation Advisory Centre (IMAC) 33, 46, 281, 599, 626, 674  
   information and resources 59, 73, 103, 105, 507

- see also under* websites
- immunisation certificates 84, 643–4
- immunisation coordinators 46, 599  
 authorisation of vaccinators 631, 634–6
- immunisation coverage 24, 84, 104–5, 624  
 diphtheria vaccines 156, 156, 160  
 hepatitis B vaccines 209  
 Hib vaccines 173  
 influenza vaccines 279–80, 280, 288, 298  
 MMR vaccines 311, 313, 364, 485, 487  
 pertussis vaccines 376  
 polio vaccines 442–3  
 tetanus vaccines 499
- immunisation history 85, 92, 284, 643  
*see also* NIR
- immunisation information 44–6, 61, 84–6, 95–7, 105–6, 626
- immunisation providers  
 guidelines *see* Guidelines for organisations storing vaccines and/or offering immunisation services  
 standards *see* Immunisation standards for vaccinators  
 vaccine storage *see* vaccine storage  
 vaccine transportation 40, 664
- immunisation registers 644
- immunisation schedules  
 NZ *see* National Immunisation Schedule  
 other countries 90, 144, 288, 343–4, 569  
 BCG vaccine 521, 522  
 pertussis vaccines 381–2, 389  
 rotavirus vaccines 462–3, 469–70  
 varicella vaccines 538, 541–2, 566
- Immunisation standards for vaccinators 40, 615  
 administration of vaccines and contraindications 622  
 adverse events reporting 622–3  
 competence and skill of vaccinators 617  
 documentation of information and patient confidentiality 620–1  
 informed consent 618–19  
 provision of safe immunisation 619–20
- immunity 15–21, 21  
 duration of 160–1, 176, 191, 213–14, 251, 288, 315–16, 381–2, 463, 502, 521, 542, 568  
 herd *see* herd immunity
- Immunization Action Coalition 676
- immunocompromise *see*  
 immunosuppression
- immunodeficiency *see*  
 immunosuppression
- immunoglobulin *see* IG
- immunosuppression 122–3, 455  
 chemotherapy *see* chemotherapy  
 contraindications and precautions 50, 51, 90, 94, 124–6, 132, 321, 527, 545, 569–70
- immunoglobulin 133, 325–6, 551, 650, 652–3, 654
- immunosuppression therapy 11, 50, 123, 126, 128–9, 132, 225, 468, 527–8  
 pneumococcal vaccines 9, 422  
 varicella and zoster 537, 550, 569–70
- live vaccines 93, 116, 468
- partial immunoglobulin deficiency 178
- primary deficiencies *see* primary immune deficiencies
- radiotherapy *see* radiotherapy
- recommended but not funded 426
- secondary deficiencies *see* secondary immune deficiencies
- vaccines and disease 7–11  
 BCG and tuberculosis 120, 516–17, 527–9  
 diphtheria 10, 57, 165  
 hepatitis A 186, 197  
 hepatitis B 7, 56, 213, 216, 225  
 Hib 7, 56, 178, 179, 182, 183  
 HPV 239–40, 242, 248–9  
 influenza 8, 289, 291  
 meningococcal 9, 57, 348  
 MMR 8, 57, 319–20, 321, 366–7, 488–9  
 pertussis 9, 384–5, 393  
 pneumococcal 9–10, 417, 418, 422, 424–6  
 polio 10, 57, 440, 442, 446  
 rotavirus 120, 454, 465, 468  
 tetanus 10, 57, 508–9



- varicella 10–11, 58, 114, 536–7, 539, 544–9, 553–4
- zoster 565, 567, 569–70
- Immunosuppression and Infection in Rheumatology Patients* 129
- impaired immunity *see* immune response; immunosuppression
- impaired lung function 8, 291
- inactivated poliomyelitis vaccine (IPV) *see* polio vaccines
- inactivated vaccines 25, 93, 190, 283, 292, 296
  - dosage and administration 53, 419, 427, 445, 653, 658
  - special groups 112–13, 123, 124
  - see also* hepatitis A vaccines; influenza vaccines; IPV
- inadequate vaccination records 54–5
- incomplete immunisation *see* interrupted immunisation
- indemnity insurance 84
- Indian peoples 379
- induration *see* swelling at injection site
- Infanrix-hexa vaccine *see* DTaP-IPV-HepB/Hib vaccine
- Infanrix-IPV vaccine *see* DTaP-IPV vaccine
- infantile hypertrophic pyloric stenosis 391–2
- infantile spasms 386
- infants 78, 207, 278, 353–4, 378–80, 455
  - catch-up programmes *see under* catch-up programmes
  - contraindications and precautions 468, 527
  - HBeAg negative mothers 207
  - HBeAg positive mothers 207, 213, 221
  - HBsAg positive mothers 207
  - hospitalised 466, 551
  - immunoglobulin 325–6
  - injections 62, 64, 65–9, 66, 67, 76–7
  - newborn *see* neonates
  - preterm *see* preterm infants
  - public health measures 390–3, 392, 557
  - recommended immunisation schedule 89–90, 134, 140, 318, 465
  - BCG vaccine 524, 531, 667
  - hepatitis B vaccines 217–18, 217
  - influenza vaccines 285–6, 291, 293
  - meningococcal vaccines 344–6, 349, 351, 355
  - pneumococcal vaccines 408, 422
  - see also* maternal antibodies
- infected skin conditions 527
- infectious diseases physicians 130, 167, 491–3, 551, 554
- inflammatory bowel disease 128–9
- inflammatory changes 481
- inflammatory disease 129
- inflammatory disorders 653
- infiximab 120, 121, 527
- influenza
  - clinical features 273–4
  - epidemiology 274–81, 276, 277, 278
  - incubation period 273
  - key information 271–2
  - public health measures 297–9, 638
  - virology 272–3
- Influenza Communication Campaign 281
- influenza vaccines 20, 100, 281–4
  - contraindications and precautions 49, 51, 294–6, 299
  - dosage and administration 288–90, 289, 419, 427, 568
  - efficacy and effectiveness 282–8, 285, 290
  - expected responses and adverse events 75, 94, 296–7
  - history of schedule 579, 590
  - immunisation uptake 85, 279–80, 280, 298
  - recommended immunisation schedule 5, 56, 99, 290–3, 291
  - special groups *see under* special groups
  - transport, storage and handling 288
  - variations from vaccine data sheets 299
- Influvac vaccine 4, 5, 119, 134–7, 140, 142, 282
  - see also* influenza vaccines
- informed consent 96, 618–19, 658, 666
  - children and consent 47
  - other settings, in 47
  - primary care, in 44–6
  - privacy and control over personal information 43–4
  - process 42–3
  - what is informed consent? 41–2

- injections 65, 510
  - infusion rates and amount 67, 71, 650, 655
  - intervals between injections *see* spacing of doses
  - needles 72, 81, 658
    - angle, gauge and length 59, 62, 62–3, 64, 65, 67
    - disposal of 664
    - needle phobia 77
    - needle-stick injuries *see* needle-stick injuries
  - preparing for vaccine administration *see under* administration of vaccines
  - site reactions 257, 419, 428, 529, 548, 570
    - abscesses at injection site 34, 64, 510
    - adverse *see* adverse events following immunisation
    - discomfort *see* discomfort at injection site
    - keloid scars 529
    - local *see* local reactions
    - muscle stiffness 655
    - nodules 64, 510
    - pain *see* pain
    - redness *see* redness at injection site
    - sores 75, 197
    - swelling *see* swelling at injection site
    - tenderness 228, 351, 655
- sites
  - alternative 60, 64
  - buttock region 64
  - deltoid *see* deltoid injection sites
  - intra-dermal *see* intra-dermal injections
  - intra-muscular *see* intra-muscular (IM) injections
  - multiple injections at same visit 54, 72–3
  - multiple injections in same muscle 73, 74
  - rubbing site 67, 77
  - separate sites 72, 89
  - skin preparation 61, 69
  - subcutaneous *see* subcutaneous (SC) injections
  - tissue necrosis 81
  - vastus lateralis *see* vastus lateralis injection sites
  - syringes 68, 81, 657
    - disposal of 664
    - pre-filled 660–2
    - removal of air bubbles 61, 61
    - same syringe 59, 657
    - separate syringes 54, 59, 72, 89
    - tuberculin 63, 81
  - tracking *see* tracking
  - vials 657–60, 663–4
- injuries
  - needle-stick *see* needle-stick injuries
  - tetanus *see* tetanus; wound management
- innate immunity 19, 19
- Institute for Vaccine Safety 676
- Institute of Environmental Science and Research *see* ESR
- Institute of Medicine (US) 100, 166, 490, 510
- institutional care 318, 347–8, 389, 546
- institutional outbreaks 199, 299
  - see also* outbreaks
- insurance 84
- intellectually handicapped individuals 481
- interferon gamma release assay 516, 526, 530
- interpreters 45
- interrupted immunisation 54–5, 89–90, 162, 259, 383, 445, 503
  - hepatitis B vaccines 215, 217, 219
  - see also* catch-up programmes
- intracranial shunts 9, 121, 422
- intra-dermal injections 63, 65, 68, 228, 654
- Intragam P immunoglobulin 326, 647, 656
  - see also* IG; IVIG
- intra-muscular (IM) injections 62–4, 71, 82, 655
- intra-vascular coagulation, disseminated 335
- intra-venous immunoglobulin *see* IVIG
- intussusception 34, 467, 469–70, 471
- invasive pneumococcal disease (IPD) 406–9, 410, 412, 415, 417–19, 426–7, 429
  - see also* pneumococcal disease
- IPOL vaccine 443–4, 447, 450
  - see also* polio vaccines

- IPV *see* polio vaccines  
 irrational behaviour 335  
 irritability 75, 335, 351, 387, 428, 448  
 irritation, local 61  
 ischaemic heart disease 8, 291  
 ischaemic stroke 548  
 isoniazid 518  
 itching 564  
 ITP *see* thrombocytopenia  
 IVIG 124–5, 647–8, 650, 653, 654–6  
     measles 326  
     varicella 550, 552
- jaundice 186, 195, 206  
 joint infection 517  
 joint pain 75, 322, 343, 490
- keloid scars 529  
 kidney transplants 7, 56, 117–18, 216,  
     218, 221–2  
 KidsHealth 675  
 killed vaccines 25  
 Koplik's spots 310, 324
- laboratory tests *see* serological tests  
 laboratory workers 57, 148, 187, 193,  
     337, 348, 447, 526  
 lacrimation 78  
 lactation *see* breastfeeding  
 lactose 29, 159, 175, 314, 540–1  
 LAIV 283–4, 288  
 laryngeal infections 240  
 laryngeal oedema 78  
 L-asparagine monohydrate 520  
 lassitude 517  
 late immunisation *see* interrupted  
     immunisation  
 latent ganglionic infection 549  
 Latin American peoples 457, 519  
 lead maternity carers 44, 91, 385, 493,  
     523–4  
 legal obligations 41–4, 627  
     notify medical officer of health *see*  
     notifiable diseases
- lesions 116  
     HPV 236, 239–40, 243, 250, 258  
     tuberculosis 517, 527–9  
     varicella and zoster 536, 549, 554,  
     565  
 leukaemia 527, 545, 549, 569  
 lifestyle risk 426  
 limb abnormalities 556
- limb pain 440  
 limb swelling 75, 388  
 limbs, aching 655  
 limpness 78–9  
 listlessness 536  
 live attenuated influenza virus vaccines  
     (LAIV) 283–4, 288  
 live vaccines 25, 95, 323, 456, 459  
     contraindications and precautions  
         49, 51, 90, 93–4, 112, 123–4, 128,  
         321, 526  
     dosage and administration 53, 61, 89,  
         127–8, 128, 282, 316, 445, 484, 543  
         between live vaccines *see under*  
         spacing of doses  
         receipt of another vaccine, blood  
         or IG 523, 651, 656  
     efficacy and effectiveness 283–4  
     special groups *see under* special  
     groups  
     *see also* BCG vaccine; measles  
     vaccines; MMR vaccines; mumps  
     vaccines; rotavirus vaccines;  
     rubella vaccines; varicella vaccines;  
     zoster vaccines
- liver disease 116, 117–19, 218, 221–2, 224  
 liver failure 206  
 liver transplants 7, 56, 117–18, 194, 206,  
     216, 218, 221–2  
 living standards 104, 441, 455  
 local immunisation coordinators *see*  
     immunisation coordinators  
 local irritation 61  
 local medical officer of health *see*  
     medical officer of health  
 local reactions 34, 284, 296, 429, 528, 654  
     injection site reactions 64, 73, 75,  
     511, 655, 658  
     specific vaccines 166, 228, 342, 351,  
     387, 448  
 local tenderness 228, 351, 655  
 localised discomfort 75  
 localised pain *see* pain  
 loss of appetite 75, 197, 428  
 loss of consciousness 78–9  
     *see also* fainting  
 loss of vision 564–5  
     *see also* blindness  
 low birthweight infants 91, 114–16, 387,  
     525  
     hepatitis B 218, 221  
     rotavirus 91, 114–16, 455, 466

- varicella 551, 556
- low platelet count 655
- lung damage 375
- lupoid 529
- lymphadenitis 34, 517, 520, 523, 528–9
- lymphadenopathy 75, 322, 480, 528
- lymphatic system conditions 569
- lymphoma 426, 527, 569
  
- macrolide use 390–2
- magnesium chloride hexahydrate 282
- magnesium sulphate heptahydrate 520
- malaise 186, 197, 206, 228, 273–4, 296, 440, 536
- malaria 138
- malignancies 258, 321, 527
- malignant neoplasms 123, 127, 565
- malnutrition 311, 455
- maltose 647–8
- mannitol 314, 540–1
- Mantoux skin testing *see* tuberculin skin testing
- manufacturers 548, 645–8
  - data sheets 30, 46, 53, 62, 64–5, 289, 354, 657, 662
  - see also specific manufacturers*
- Māori peoples 188, 242–3, 338, 457, 519, 539
  - hepatitis B 209–11, 221, 224
  - influenza 275–7, 281
  - pertussis 377, 379
  - pneumococcal disease 408–9, 412
- mastitis 362
- maternal antibodies 20, 160, 191, 325, 454
  - influenza 112, 286, 292
  - pertussis 113, 384, 505
- maternal fetal medicine specialists 493
- maternal rubella 480–1, 485
- maternal tetanus 499
- maternal varicella 537
- maternally derived immunity 20
- maternity wards 389, 394
- MCV4-D vaccine 27, 341
  - dosage and administration 346, 419
  - efficacy and effectiveness 344
  - expected responses and adverse events 351–2
  - not funded but recommended 350
  - recommended immunisation schedule 347, 348, 349
- special groups 118, 134–7, 139–42, 349
- variations from vaccine data sheets 355
  - see also* meningococcal vaccines
- MCV4-T vaccine 341–2, 345–7, 350, 352
  - see also* meningococcal vaccines
- measles 133
  - clinical features 310–11
  - epidemiology 22, 99, 104, 311–13, 313, 364
  - incubation period 310
  - key information 309–10
  - public health measures 324–7, 649, 652
  - virology 310
- measles vaccines 313–14
  - catch-up programmes 318–19, 600–1
  - contraindications and precautions 319–21, 325
  - dosage and administration 316–17
  - efficacy and effectiveness 315–16
  - expected responses and adverse events 322–3
  - history of schedule 577, 590–1
  - recommended immunisation schedule 317–20, 317
  - single-antigen vaccine 486
  - transport, storage and handling 316
  - variations from vaccine data sheets 328
    - see also* MMR vaccines; MMRV vaccines
- medical officer of health 12, 318, 324
  - authorisation of vaccinators 39, 629–38
  - BCG vaccine 524–5, 529
  - notifiable diseases *see* notifiable diseases
  - public health measures 326, 353–4, 369, 393–4, 491, 638–9
- Medical Practitioner Supply Order 81
- medical practitioners *see* general/medical practitioners
- Medicines Act 1981 646
- Medicines Classification Committee (MCC) 39, 629
- Medicines Regulations 1984 39, 629
- Medium 199 159, 190
- Medsafe 2, 30–1, 36, 62, 65, 252, 674
  - see also under* websites

- men who have sex with men 56, 150,  
193, 195, 217, 239, 242, 249–51, 254
- Menactra vaccine *see* MCV4-D vaccine
- MenCCV vaccine 27, 341  
dosage and administration 345–6  
expected responses and adverse  
events 351  
not funded vaccines 350  
recommended immunisation  
schedule 348, 349  
special groups 117, 134–5, 139–41  
variations from vaccine data sheets  
355  
*see also* meningococcal vaccines
- meningitis 172–3, 322, 335, 362, 364,  
407, 415–16, 440, 517, 520, 570, 656
- Meningococcal B Immunisation  
Programme 587
- meningococcal bacteraemia 334
- meningococcal disease  
bacteriology 334  
clinical features 334–5, 335  
epidemiology 336–40, 338, 339, 340  
group A 334, 336, 354  
group B 334, 336, 338–9, 339,  
340, 349  
group C 334, 336, 338–9, 339,  
340, 349, 351  
group W and Y 334, 336, 339,  
340, 350  
incubation period 337  
key information 333–4  
public health measures 352–5
- meningococcal vaccines 340–3, 341  
boosters 343–4, 345, 349, 351, 355  
contraindications and precautions  
350  
dosage and administration 345–6,  
419  
efficacy and effectiveness 343–5  
expected responses and adverse  
events 342, 351–2  
history of schedule 579  
recommended immunisation  
schedule 57, 120, 346–50, 348, 349  
reconstitution 345  
special groups *see under* special  
groups  
transport, storage and handling 345  
vaccines 340–3, 352  
group B 341, 342–3  
group C conjugate 27, 131–5,  
139–41, 340–1, 345–7, 348,  
350, 351–2, 354, 355  
quadrivalent meningococcal  
conjugate (ACYW135) 131–7,  
139–43, 340–2, 344–7, 348,  
350, 351–2, 354, 355  
quadrivalent meningococcal  
polysaccharide 27, 340, 344–5  
recombinant group B 342–3  
variations from vaccine data sheets  
355
- mental retardation 481
- MeNZB vaccine 342, 579  
*see also* meningococcal vaccines
- mercury 29
- Meruvax II vaccine 314  
*see also* MMR vaccines; rubella  
vaccines
- mesenteric adenitis 310
- metabolic disorder 8, 11, 58, 121, 274,  
291, 467, 544
- methaemoglobinaemia 77
- methotrexate 128, 570
- MF59 emulsion 29
- microbiologists 324, 449, 491–2
- microcephaly 481
- Middle Eastern peoples 457, 519
- midwives 39  
*see also* lead maternity carers
- migrants *see* immigrants
- military accommodation 336, 347–8,  
353
- military personnel 148, 193, 546
- Ministry of Health 2–3, 280, 449, 673,  
677, 679  
gazetted BCG vaccinators 632  
immunisation standards *see*  
Immunisation standards for  
vaccinators
- National Immunisation Programme 3
- payment claim forms 84
- recommendations 183, 259, 354–5,  
394–5, 429–30, 450, 471, 531, 558,  
571  
influenza vaccines 294, 299  
MMR vaccines 318, 328
- resources and information 44–7,  
599, 626, 633  
*see also under* websites
- miscarriage 311

- missed vaccinations *see* interrupted immunisation
- Mitigating Vaccination Pain and Distress* 59
- MMR (measles, mumps and rubella) vaccines 125, 313–14, 363–4, 483  
autism, and 99, 323  
catch-up programmes 318–19, 600–1, 604, 608–10  
contraindications and precautions 125, 319–21, 325, 366, 367, 487–8, 489  
dosage and administration 89, 215, 316–17, 484–5, 488, 523, 543, 601, 659  
efficacy and effectiveness 104, 315–16, 364, 484, 542  
expected responses and adverse events 75, 94, 322–3, 486, 490  
history of schedule 578, 590–1, 594–5  
interchangeability of 317, 365, 485  
prophylaxis, as 324–7, 649, 652  
recommended immunisation schedule 5, 57, 317–20, 317, 365–7, 365, 485–9, 485, 612  
risk of transmission 95, 123, 319, 323, 366, 480, 488  
special groups *see under* special groups  
transport, storage and handling 316, 364–5, 484  
variations from vaccine data sheets 328
- MMR II vaccine 4, 314, 317, 364, 365, 483, 485  
*see also* MMR vaccines
- MMRV (measles, mumps, rubella and varicella) vaccines 314, 363, 483, 540–1  
contraindications and precautions 545, 550  
dosage and administration 543  
efficacy and effectiveness 542  
expected responses and adverse events 550  
recommended immunisation schedule 543  
transport, storage and handling 542–3
- monoclonal antibody therapy 57, 120, 121, 348, 468, 527, 653
- monopotassium phosphate 159
- monosodium glutamate (MSG) 29
- monosodium L-glutamate 540, 567
- morbidity  
hepatitis A 193–4  
influenza 274, 292–3, 296  
measles 311  
pertussis 376–80, 394  
pneumococcal disease 407, 415–16  
rubella 481  
varicella zoster virus 536, 538
- mortality 34, 104, 138, 157  
cervical cancer 243, 258  
diphtheria 155, 156  
hepatitis A 193–4  
hepatitis B 206, 223  
influenza 274–8, 277, 280–1, 287, 293, 296, 299  
measles 311  
meningococcal disease 335–6, 339  
mumps 362  
pertussis 375–7, 389  
pneumococcal disease 407, 409, 415–16  
poliomyelitis 441  
rotavirus 455, 462  
rubella 480, 481  
tetanus 498, 500, 501–2  
tuberculosis 518, 521, 529  
varicella 537–9, 556
- mothers 95, 389, 557  
infected with hepatitis B *see under* HBsAg positive  
*see also* maternal antibodies
- MRC-5 cells 540, 567
- MSD (Merck Sharp and Dohme) 212, 247, 314, 364, 460, 483, 540, 567
- MSG 29
- multi-organ disease 565
- multiple sclerosis 228
- multiple vaccinations 54, 72–3, 74  
*see also* injections
- mumps  
clinical features 362  
epidemiology 315–16, 362–3  
key information 361  
public health measures 368–9, 649  
virology 361
- mumps vaccines 363–4  
contraindications and precautions *see under* MMR vaccines  
dosage and administration 365

- efficacy and effectiveness 364  
 expected responses and adverse events *see under* MMR vaccines  
 history of schedule 591  
 interchangeability of 365  
 recommended immunisation schedule 365–7, 365  
 single-antigen vaccine 363  
 transport, storage and handling 364–5  
*see also* MMR vaccines; MMRV vaccines  
 Mumps vaccine 314  
*see also* MMR vaccines; mumps vaccines  
 muscle hypotonia 78–9  
 muscle spasms 498  
 muscle stiffness 655  
 myalgia 206, 229, 273, 296, 335, 427  
 myeloma 426  
 Mylan EPD (BGP Products Pty Ltd) 282  
 myocarditis 155, 274, 310  
 myositis 274  
  
 narcolepsy 297  
 nasal congestion 78  
 National Antenatal HIV Screening Programme 527  
 National Centre for Immunisation Research & Surveillance (NCIRS) 676  
 National Cervical Screening Programme 259  
*National Guidelines for Vaccine Storage and Transportation for Immunisation Providers 2017* 40  
 National Hepatitis B Screening Programme 210  
 National Immunisation Programme 3  
 National Immunisation Register *see* NIR  
 National Immunisation Schedule 2–3, 5, 7–11, 84, 615  
   catch-up guides 606, 607–11  
   changes in 2017 4, 6  
   history of 575–80, 587–97  
   not on schedule *see* not funded vaccines  
   previous schedules 581–6  
   rest of schedule following AEFI 90  
   steps if interrupted *see* interrupted immunisation  
   vaccines available free of charge *see* funded vaccines  
  
 National Influenza Specialist Group 281, 677  
 National Measles Laboratory 324  
*National Poliomyelitis Response Plan for New Zealand 449*  
 National Serosurvey of Vaccine Preventable Diseases 157  
 natural immunity 101  
 natural infection *see* wild-type virus  
 naturally acquired immunity 20  
 nausea 75, 78–9, 186, 197, 206, 228, 335, 655  
 nebulised adrenaline 83  
 nebulised salbutamol 83  
 needle phobia 77  
 needles *see under* injections  
 needle-stick injuries 7, 56, 208, 216, 225, 657, 665–6  
 negligence claims 84  
 NeisVac-C vaccine *see* MenCCV vaccine; meningococcal vaccines  
 neomycin 48, 190, 443, 540, 567  
   reactions to 321, 367, 489, 547, 569  
 neomycin sulphate 159, 189–90, 314, 540–1  
 neonatal tetanus 499, 501  
 neonatal units 385, 389, 394, 466, 546  
 neonatal varicella infection 537  
 neonates 91, 100–1, 172, 223, 466, 551, 554  
   BCG vaccine 520, 521, 524–5, 527, 667  
   influenza 286, 292  
   pertussis 385, 389, 390–1  
   *see also* HBsAg positive; maternal antibodies  
 nephritis 362  
 nephrotic syndrome 9, 132, 178, 417, 422, 426  
 nerve deafness 322, 362, 481  
 nervousness 37  
 neuralgia 564, 567–8  
 neuritis 362  
 neurodevelopmental disability 388  
 neurological conditions 51, 93, 295, 386, 395, 490, 529, 539  
 neurological damage 310, 480  
 neuromuscular disease 8, 291  
 New Zealand Blood Service *see* NZBS  
 New Zealand Cot Death Study 100, 386  
*New Zealand Influenza Pandemic Plan 299*  
 New Zealand Medicines and Medical Devices Safety Authority *see* Medsafe

- New Zealand National Certification Committee for the Eradication of Polio 442
- New Zealand National Immunisation Schedule *see* National Immunisation Schedule
- New Zealand Paediatric Surveillance Unit (NZPSU) 34, 442, 449
- New Zealand Pharmacovigilance Centre 31  
*see also* CARM reporting
- New Zealand Public Health and Disability Act 2000 44
- New Zealand Resuscitation Council 638
- newborn babies *see* neonates
- newborn infant contact 551  
*see also* household and close contacts
- night sweats 517
- Nimenrix vaccine *see* MCV4-T vaccine; meningococcal vaccines
- NIR 43–5, 83–6, 525, 624–5, 658
- nodules at injection site 64, 510
- non-consensual sexual intercourse 7, 56, 216, 225
- non-funded vaccines *see* not funded vaccines
- non-residents 12, 251, 255, 605, 612, 625
- Normal Immunoglobulin-VF 198–9, 325–6, 646, 649, 650, 652, 654–6  
*see also* IG
- not funded vaccines 90, 638–9
- hepatitis A vaccines 56, 193–4
  - hepatitis A-Hepatitis B vaccines 118, 227
  - hepatitis B vaccines 56, 217
  - HPV vaccines 56, 254, 254, 255–6
  - influenza vaccines 56, 115, 130, 291, 293–4, 298
  - meningococcal vaccines 57, 347, 348, 349–50, 350
  - pertussis vaccines 57, 113–15, 385, 395, 612
  - pneumococcal vaccines 57, 426
  - polio vaccines 445, 447
  - tetanus vaccines 57, 163–4, 167, 504–6
  - varicella vaccines 58, 112, 114, 142, 145, 543–7
  - zoster vaccines 569
- notifiable diseases 12–13
- diphtheria 166
  - hepatitis A 198
  - hepatitis B 209, 218, 229
  - Hib disease 181
  - influenza 299
  - measles 312, 324
  - meningococcal disease 335, 352
  - mumps 368
  - pertussis 377–8, 390
  - pneumococcal disease 429
  - poliomyelitis 448–9
  - rubella and CRS 482, 490, 493
  - tetanus 511
  - tuberculosis 518, 530
- notifications
- congenital rubella syndrome 482
  - diphtheria 157
  - hepatitis A 188, 189
  - hepatitis B 209–10, 210
  - Hib disease 173, 174
  - measles 312, 313
  - meningococcal disease 337–9, 338
  - mumps 363
  - pertussis 376–8, 378, 379
  - pneumococcal disease 408–9, 410, 411
  - poliomyelitis 442
  - rubella 481–2, 483
  - tetanus 500
  - tuberculosis 518–19
- Novartis 29
- nurses 39, 47, 147, 148, 385, 632
- Nursing Council of New Zealand 43, 631
- nursing homes *see* rest homes
- NZ Youth'12 survey 242
- NZBS 198, 326, 550, 645–8
- accessing IG or contacting them for advice 648–9, 655
- obesity 213, 281
- obstetric units 546
- obstetricians 491–3
- obstructive pulmonary disease 287
- occupational risk 56, 146, 147–9, 193–4, 217, 225, 612, 657, 665–6
- Oka strain of varicella 540, 549
- older adults 345, 387, 455, 565–7
- not funded but recommended 57, 291, 569
  - pneumococcal vaccines 408, 417, 419, 426



- recommended immunisation
  - schedule 183
  - influenza vaccines 56, 276–7, 279, 282, 284–7, 291, 293
  - tetanus 498, 500
- older children 79, 288, 457
  - catch-up programmes 466, 504, 604–5, 606
  - injections 63, 64, 71–2, 77
  - recommended immunisation
    - schedule 163, 289, 424
- oleic acid 29
- oncologists 130
- oncology patients 130–1
- ophoritis 362
- operations 93, 139
- OPV 442–3, 445–6, 576
  - see also* polio vaccines
- oral contraceptive pill 354
- oral poliomyelitis vaccine 442–3, 445–6, 576
  - see also* polio vaccines
- oral vaccine administration 62, 65
  - rotavirus vaccines 459, 464, 662
- orchitis 362, 364
- organ transplants 10, 123, 126, 213, 225, 242, 249, 537, 544, 565
  - recommended immunisation
    - schedule 56–8, 132–3, 165, 446–7, 508–9, 569
    - hepatitis B vaccines 7, 216, 222–3
    - Hib vaccines 7, 179
    - meningococcal vaccines 9, 348
    - pertussis vaccines 9, 384–5
    - pneumococcal vaccines 9–10, 422, 424–5
- oropharyngeal cancers 236–7, 240, 242, 244–5
  - see also* cancer
- osteitis/osteomyelitis 34, 520, 529
- otitis media 274, 310, 375
  - Hib disease 172, 175
  - pneumococcal disease 407, 417
- outbreaks
  - community 195, 199
  - diphtheria 157, 160–1
  - hepatitis A 187–8, 192–4, 198–9
  - Hib disease 173
  - influenza 272, 274, 294, 298–9
  - institutional 199, 299
  - measles 312, 315, 318, 320, 324–5
  - meningococcal disease 354–5
  - mumps 363, 364, 366, 369
  - pertussis 113, 389
  - rotavirus 455, 458
  - rubella 481–2, 484–6
  - varicella zoster virus 541
  - see also* epidemics; pandemics
- outer membrane vesicle vaccines 342
- outpatient settings 389
- overseas travel 145–6, 312, 445–7, 505, 526, 546, 656, 679
  - diphtheria vaccines 157, 164
  - hepatitis A vaccines 187–8, 193–4, 197
  - hepatitis B vaccines 208, 209, 217
  - influenza vaccines 291, 294
  - meningococcal vaccines 150, 347
  - MMR vaccines 318, 320, 482, 491
- Pacific peoples 188, 242, 338, 457, 539
  - hepatitis B 210–11, 221, 224
  - influenza 275–8, 281
  - pertussis 377, 379
  - pneumococcal disease 408–9, 412
  - tuberculosis 519, 522
- paediatric units 539, 546
- paediatricians 93, 527, 547
- pain 59, 71, 75–7, 510, 564, 656
  - diphtheria vaccines 75, 166
  - hepatitis B vaccines 75, 228
  - Hib vaccines 75, 180
  - HPV vaccines 75, 257
  - meningococcal vaccines 343, 351
  - pertussis vaccines 75, 387
  - pneumococcal vaccines 75, 428
  - polio vaccines 440, 448
  - varicella vaccines 75, 548
  - see also* abdominal pain; joint pain
- palivizumab 653
- pallor 78–9
- pancreatitis 362
- pandemic planning and response 677
- pandemics
  - influenza 273–4, 280–1, 286, 299
  - see also* epidemics; outbreaks
- paracetamol 76, 77
- paralysis 155, 440–1
- parents/guardians 95, 394
  - advice and information 45–6, 72–3, 326, 391, 470, 491, 525, 554
  - AEFI reporting process 33
  - alternatives to pertussis-containing vaccines 162, 504

- informed consent 42, 44, 47, 69, 96, 665–6
- personal information 85, 525, 643
- post-vaccination 74, 77, 321, 427
- request vaccines 90, 317, 366, 486, 525, 601
- during vaccination 48, 60, 65–6, 70, 70
- paroxysmal coughing 374–5, 390, 393
- partial immunoglobulin deficiency 178
- partially immunised children and adults 54–5, 57, 156, 181, 445, 463, 466, 504
- passive immunisation with IG *see* IG
- passive immunity, maternally acquired *see* maternal antibodies
- passive smoking 337
- passively acquired immunity 20
- PCV vaccines *see* pneumococcal vaccines
- PCV7 vaccine 407–9, 412, 428, 592 *see also* pneumococcal vaccines
- PCV10 vaccine 4, 409, 414
  - dosage and administration 419, 429, 543
  - efficacy and effectiveness 415–17
  - expected responses and adverse events 428
  - recommended immunisation schedule 5, 9, 420, 420
  - variations from vaccine data sheets 429 *see also* pneumococcal vaccines
- PCV13 vaccine 27, 408–9, 414
  - contraindications and precautions 427
  - dosage and administration 290, 296, 346, 419, 427
  - efficacy and effectiveness 417–18
  - expected responses and adverse events 428
  - not funded but recommended 426
  - recommended immunisation schedule 4, 420–1, 422–3, 424, 425, 427
  - special groups 6, 57, 116–18, 121, 124–5, 130–1, 134–7, 139–42, 422–3, 424, 425, 427
  - variations from vaccine data sheets 429 *see also* pneumococcal vaccines
- penicillins 166–7, 335, 413
- pericarditis 274, 362, 517
- perineal burning 78
- peripheral perfusion, poor 335
- peritonitis 132, 517
- persistent, inconsolable screaming 34, 388
- personal information 43–4, 85, 525, 620–1
- pertussis
  - bacteriology 374
  - clinical features 374–5
  - epidemiology 22, 100–1, 105, 375–80
  - incubation period 374
  - key information 373–4
  - public health measures 388–94
- pertussis vaccines 20, 380
  - alternatives to 162–3, 504
  - boosters 130, 380, 383, 385, 394
  - catch-up programmes 394–5
  - contraindications and precautions 51, 93, 386, 395
  - dosage and administration 382
  - efficacy and effectiveness 105, 113, 376, 381–2, 389
  - expected responses and adverse events 75, 386–8, 388
  - history of schedule 575, 591–2
  - not funded but recommended *see under* not funded vaccines
  - recommended immunisation schedule 57, 383–4, 383
  - special groups *see under* special groups
  - transport, storage and handling 382
  - variations from vaccine data sheets 394–5
- Pfizer NZ Ltd 341–2
- phagocytic function deficiency 122–3, 126
- PHARMAC 2–3, 111, 673–4
- Pharmaceutical and Therapeutics Advisory Committee (PTAC) 2
- Pharmaceutical Society of New Zealand (PSNZ) 631
- Pharmacist Vaccinator Statement* 627
- pharmacist vaccinators 39, 627
  - authorisation of 630–7
  - resuscitation requirements 637–8
  - training of 630–1
- Pharmacy Council of New Zealand (PCNZ) 627, 631
- phenol 414
- phenoxyethanol 190, 443
- phosphate 414
- phosphate salts 189

- pig influenza virus 273
- planning pregnancy 111–12, 487
- playmate contact 551  
*see also* household and close contacts
- pleurisy 517
- plumbers 149
- pneumococcal community-acquired pneumonia (CAP) 418
- pneumococcal disease  
 bacteriology 406, 406  
 clinical features 406–7  
 epidemiology 100–1, 407–13  
   23PPV serotype 406  
   PCV7 serotype 406, 407, 409, 411  
   PCV10 serotype 406, 409, 411, 411  
   PCV13 serotype 406, 409, 411, 411  
 incubation period 407  
 key information 405  
 public health measures 429
- pneumococcal vaccines 413–14  
 boosters 130, 417, 420, 602  
 catch-up programmes 601–2, 607–9  
 contraindications and precautions 427–8  
 dosage and administration 289–90, 296, 346, 419–20, 427, 601–2  
 efficacy and effectiveness 101, 415–19  
 expected responses and adverse events 75, 427, 428–9  
 history of schedule 580, 592–3  
 interchangeability of 429  
 not funded but recommended 57, 426  
 recommended immunisation schedule 57, 90, 420–5  
 special groups *see under* special groups  
 transport, storage and handling 419  
 vaccines  
   pneumococcal conjugate vaccines *see under* conjugate vaccines  
   pneumococcal polysaccharide vaccines 413, 428–9  
 variations from vaccine data sheets 429–30
- pneumonia 172, 274, 310–11, 375, 537  
 pneumococcal disease 407–8, 412, 416, 418–19
- Pneumovax 23 vaccine *see* 23PPV vaccine; pneumococcal vaccines
- police 148
- polio eradication 441–2, 449
- polio vaccines 442–3, 443, 450  
 boosters 130–1, 445, 447  
 catch-up programmes 610  
 contraindications and precautions 446, 447–8  
 dosage and administration 444–5, 446  
 efficacy and effectiveness 443–4  
 expected responses and adverse events 448  
 history of schedule 576, 593–4  
 recommended immunisation schedule 57, 445–7, 445  
 special groups 125, 130–1  
 transport, storage and handling 444  
 variations from vaccine data sheets 450
- poliomyelitis  
 clinical features 440–1  
 epidemiology 441–3  
 incubation period 440  
 key information 439  
 public health measures 448–9  
 risk of transmission 440  
 virology 440
- polyalcohols 540
- polymyxin B 443
- polymyxin B sulphate 159
- polysaccharide vaccines 26–8, 101, 289–90  
 meningococcal 27, 340, 344–5  
 pneumococcal 27–8, 413–14, 428–9  
 special groups 120, 121, 125, 139
- polysorbate 20 159, 189–90
- polysorbate 80 29, 103, 159, 282, 414, 443, 460
- polysplenia *see* asplenic children and adults
- porcine circovirus 469
- post-exposure prophylaxis 198–9, 352–4, 649  
 MMR 310, 324–6, 368, 484, 491–3  
 pertussis 390–4, 392  
 tetanus 506–8, 507  
 varicella 10, 58, 544, 550–4, 553  
*see also* IG
- post-herpetic neuralgia 564, 567–8
- post-partum 113, 114, 384, 488
- post-polio syndrome 441
- postponed immunisation *see* delayed immunisation

- postural orthostatic tachycardia syndrome (POTS) 102–3
- potassium chloride 159, 282, 540, 567
- potassium phosphate 540
- potassium phosphate monobasic 282, 567
- poultry workers 149
- practice management system (PMS) 83–4
- prednisone 9, 83, 127–9, 128, 422, 547
- pre-filled syringes 660–2
- pregnancy
  - contraindications and precautions 50
    - drugs 182, 527
    - live vaccines 50–1, 112, 320–1, 328, 367, 487, 489, 526–7, 547, 570, 612
    - non-live vaccines 197, 256, 446, 448, 558
  - public health measures 353–4, 390–1, 491–3
    - IG 325–6, 551, 554–6, 555, 557
  - recommended and/or safe 111–12, 164, 350, 427, 501, 505
    - influenza vaccines 8, 56, 95, 112–13, 286, 291, 292, 299
    - pertussis vaccines 9, 57, 95, 113, 115, 384, 387, 388–9, 395, 612
  - risk of infection 311, 362, 393, 468, 523, 554–6
    - hepatitis B 213, 218, 221, 223
    - influenza 276–7, 281, 286, 299
    - rubella 111, 480–2, 485, 491–2
  - special groups 50–1, 179, 292, 299, 527
  - stages of pregnancy
    - planning pregnancy 111–12, 487
    - post-partum *see* post-partum
    - during pregnancy 112–13, 446, 487–8, 505
  - termination of 489, 493
    - see also* antenatal screening; breastfeeding
- premature infants *see* preterm infants
- preservatives 29
  - IG 646–8, 650
  - specific vaccines 212, 247–8, 414, 443, 460, 567
- preterm infants 221, 311, 387, 409, 455, 466, 551, 556
  - conditions that are not
    - contraindications 52, 91
    - contraindications and precautions 48, 525, 528
    - recommended immunisation schedule 9, 114–16, 218, 422, 466
- Prevenar 7 vaccine *see* PCV7 vaccine; pneumococcal vaccines
- Prevenar 13 vaccine *see* PCV13 vaccine; pneumococcal vaccines
- previous dose reactions 48, 388, 427
  - anaphylaxis 48, 51, 90, 94, 165, 180, 197, 228, 256, 294, 320–1, 350–1, 367, 386, 395, 447, 467, 489, 547
  - hypersensitivity 509–11
- primary health care 44–6
- primary immune deficiencies 7, 10, 119–20, 122, 124–6, 547, 569, 649–50
  - BCG vaccine 124–6, 527, 529
  - pneumococcal vaccines 9–10, 57, 124–5, 422, 424–5
- primary immune response 16–17, 18
- Primary Maternity Services Notice 2007 44
- Priorix vaccine 4, 5, 314, 363, 483, 541
  - interchangeability of 317, 365, 485
  - special groups 117–18, 135–7
  - see also* measles vaccines; MMR vaccines
- Priorix-Tetra vaccine (MMRV) 314, 541
  - see also* measles vaccines; MMRV vaccines
- prisons 147–8, 217, 546
- privacy 43–4, 85–6
- Privacy Commissioner 44
- Privigen immunoglobulin 647–8, 656
  - see also* IG
- profound unilateral nerve deafness 362
- proline 647
- properdin deficiency 125, 336
- prophylaxis 429
  - antimicrobial *see* antimicrobial prophylaxis
  - chemo *see* chemoprophylaxis
  - post-exposure *see* post-exposure prophylaxis
  - rifampicin *see* rifampicin chemoprophylaxis
  - see also specific drugs*
- ProQuad vaccine 314, 540
  - see also* MMRV vaccines
- prostitutes 149, 217, 225

- PRP-OMP Hib vaccine 174  
*see also* Hib vaccines
- PRP-T Hib vaccine 174  
*see also* Hib vaccines
- pruritus 78, 257, 322
- psychological support 65
- Public Health Emergency of  
 International Concern 449
- public health nurses *see* nurses
- pulmonary disease 274
- purpura 322
- pyloric stenosis 391
- pyrexia 257  
*see also* fever
- quadrivalent human papillomavirus  
 vaccine *see* HPV4 vaccine
- quadrivalent inactivated vaccines  
 (QIVs) 283
- quadrivalent meningococcal vaccines  
*see* MCV4-D vaccine; MCV4-T  
 vaccine; meningococcal vaccines
- quadrivalent MMRV vaccines *see*  
 MMRV vaccines
- questions and concerns  
 addressing issues in a constantly  
 changing environment 105–6  
 commonly asked questions  
 allergies and illnesses 92–4  
 babies and children 91–2  
 parents, guardians and contacts  
 95  
 vaccine scheduling 89–90
- myths and concerns about  
 immunisation 95–6  
 addressing concerns 97–8  
 debunking myths 98–105  
 understanding anti-immunisation  
 96–7
- rabies immunoglobulin (RIG) 645–6,  
 652
- radiotherapy 9, 123, 321, 422, 527
- Ramsay-Hunt syndrome 570
- rashes 79, 94, 95, 335, 427, 656  
 MMR 75, 310–11, 322, 324, 480, 490  
 varicella and zoster 123–4, 536, 545,  
 547, 549–50, 564, 570
- reactions  
 adverse *see* adverse events following  
 immunisation  
 allergic *see* allergic reactions  
 common responses *see* expected  
 responses  
 injection site *see under* injections  
 local *see* local reactions  
 previous dose of vaccine *see* previous  
 dose reactions  
 serious *see* serious reactions  
 systemic *see* systemic reactions  
 vaccine components, to *see* vaccine  
 components
- recall system 92, 219  
*see also* revaccination
- recombinant vaccines 26
- records *see* documentation and records
- redness at injection site 75, 180, 197,  
 228, 297, 351, 387, 428, 548
- refrigerators 41
- refugees 143–5, 157, 224
- Registered Nurse Scope of Practice 43
- registered nurses *see* nurses
- re-immunisation *see* revaccination
- renal dialysis 9, 56–8, 165  
 hepatitis B vaccines 56, 216, 218, 223  
 Hib vaccines 7, 56, 179  
 pertussis vaccines 57, 384–5  
 pneumococcal vaccines 10, 57, 425  
 polio vaccines 57, 447  
 tetanus vaccines 57, 508–9
- renal failure 116, 117–19, 132, 213, 656  
 pneumococcal vaccines 9, 117–18,  
 132, 422  
 varicella vaccines 58, 117, 544
- renal infection 517
- replacement therapy 124, 570, 650, 653
- residential care facilities *see* rest homes
- residuals 30
- Resource Management Act 1991 664
- respiratory failure 274
- respiratory illness 8, 287, 291, 292
- respiratory obstruction 155
- respiratory papillomatosis 236, 240
- respiratory syncytial virus 653
- respiratory tract infections 175, 337, 467
- respiratory viral infections 296
- responsiveness, altered 335
- rest homes 147, 187, 287–8, 291, 318, 455
- resuscitation of patients 637–8
- revaccination 139, 143, 164–5, 179, 223,  
 384–5, 429, 446–7, 508–9  
 BCG vaccine 522–3, 526  
 MMR vaccines 133, 319, 366, 488  
 pneumococcal vaccines 116, 421, 425

- see also* recall system
- Reye syndrome 274, 386, 548
- Rhesus anti-D IG 488, 646
- rheumatic heart disease 8, 291
- rheumatoid arthritis 565
- rheumatological diseases 126, 128–9, 129
- rhinitis 273
- rhinorrhoea 374
- rifampicin chemoprophylaxis 181–2, 337, 353–4, 518  
*see also* chemoprophylaxis
- RIG (rabies immunoglobulin) 645–6, 652
- rigors 655
- risk factors 146, 150, 209
- risk of transmission 21–3, 229, 440, 519, 647–8  
MMR vaccines *see under* MMR vaccines  
rotavirus vaccines 91, 466, 468  
varicella vaccines 95, 549
- Rotarix vaccine *see* rotavirus vaccines;  
RV1 vaccine
- RotaShield vaccine 469
- RotaTeq vaccine *see* rotavirus vaccines;  
RV5 vaccine
- rotavirus  
clinical features 454–5  
epidemiology 21, 455–9, 458, 459  
incubation period 454  
key information 453  
notifiable diseases 12  
public health measures 455, 458, 471  
variations from vaccine data sheets 471  
virology 454
- rotavirus vaccines 459–60  
catch-up programmes 466, 607  
contraindications and precautions 125, 467–8, 471, 656  
dosage and administration 53, 65, 76, 89, 464, 471, 523, 601, 652–3, 657, 662  
efficacy and effectiveness 460–3, 461  
expected responses and adverse events 34, 75, 469–70  
history of schedule 580, 594  
interchangeability of 464, 601  
recommended immunisation schedule 464–7, 465  
risk of transmission 91, 466, 468  
shedding 468  
special groups *see under* special groups  
transport, storage and handling 463
- rubbing injection sites 67, 77
- rubella 319  
clinical features 480–1  
epidemiology 99, 364, 481, 482–3, 483  
incubation period 480  
key information 479  
public health measures 481, 490–3, 649  
virology 480
- rubella vaccines 55, 483  
contraindications and precautions 487–8, 489  
dosage and administration 484–5  
efficacy and effectiveness 484  
expected responses and adverse events 486, 490  
history of schedule 577, 594–5  
interchangeability of 485  
recommended immunisation schedule 485–9, 485  
risk of transmission 480, 488  
single-antigen vaccine 483  
transport, storage and handling 484  
*see also* MMR vaccines; MMRV vaccines
- RV1 vaccine 460  
catch-up programmes 466, 607  
contraindications and precautions 468  
dosage and administration 464  
efficacy and effectiveness 461, 463  
expected responses and adverse events 469–70  
history of schedule 580, 594  
interchangeability of 601  
recommended immunisation schedule 5, 464–6, 465  
variations from vaccine data sheets 471  
*see also* rotavirus vaccines
- RV5 vaccines 4  
efficacy and effectiveness 461, 463  
expected responses and adverse events 469–70  
history of schedule 460, 480, 580, 594  
interchangeability of 464, 601  
recommended immunisation schedule 465  
transitioning from 464–5, 465, 607  
*see also* rotavirus vaccines

- Sabin poliomyelitis vaccine 576  
*see also* polio vaccines
- Sabin polioviruses 442
- safe immunisation processes 619–20  
 adverse events *see* adverse events  
 following immunisation  
 informed consent *see* informed consent  
 vaccinator training 65, 625, 630–6  
 vaccine administration *see*  
 administration of vaccines
- safer sex approaches 259
- safety  
 during administration 69  
 approval of vaccines in NZ 30–1  
 immunoglobulin 645  
 spontaneous reporting of adverse reactions 31–8  
 vaccines 97–8, 103, 112, 120  
 diphtheria vaccines 163, 387–8,  
 504, 601, 604  
 hepatitis A vaccines 197  
 Hib vaccines 183  
 HPV vaccines 103, 251, 256, 257,  
 259  
 influenza vaccines 295, 297  
 live vaccines 127–8  
 meningococcal vaccines 351–2  
 MMR vaccines 315, 364  
 pertussis vaccines 113, 387–8,  
 601, 604  
 pneumococcal vaccines 428  
 rotavirus vaccines 464, 466–70  
 tetanus vaccines 163, 387–8, 504,  
 510, 601, 604  
 varicella vaccines 545, 547  
 zoster vaccines 567, 570  
*see also* WHO
- salicylates 548
- saline solution 175, 189
- salivary gland swelling and tenderness  
 322, 362
- Salk poliomyelitis vaccine *see* IPV
- same syringe 59, 657
- Sanofi 159, 175, 190, 282–3, 341, 380,  
 443, 501
- scars 556, 564
- school carers 147
- school teachers 147
- School-based Vaccination System  
 (SBVS) 83–4, 86
- schools 147, 336
- immunisation certificates and  
 register 643–4  
 informed consent in 47  
 public health measures 199, 389  
 exclusion 167, 326–7, 368–9,  
 393–4, 491, 554
- SCID 120, 125, 467
- screaming 388, 470
- screening 531  
 antenatal *see* antenatal screening  
 cervical 258–9  
 hepatitis B 210, 218, 224–5  
 tuberculosis *see* tuberculin skin  
 testing
- secondary bacterial skin infections 537
- secondary immune deficiencies 123,  
 126–37, 569, 649–50
- secondary immune response 17, 18
- seizures 34, 77, 79, 93–4, 180, 321,  
 388, 462  
 febrile *see* febrile seizures
- semi-closed communities 336  
*see also* communal accommodation
- separate injection sites 72, 89
- separate syringes *see under* injections
- sepsis 34, 132, 138, 335, 539
- septic arthritis 172
- septicaemia 172
- Seqirus (NZ) Ltd 159, 247, 282, 501, 520
- serious reactions 34, 448, 509  
 HHE 34, 79–80, 388
- serological tests 221–2, 390, 654, 665  
 hepatitis B 91, 133, 205–6, 205, 219–  
 21, 220, 224–8, 225, 226, 230  
 MMR 320, 322, 324, 487, 490–3  
 varicella 546, 550, 556
- severe combined immune deficiency  
 (SCID) 120, 125, 467
- severe reactions 427
- sewage workers 149, 193
- sex workers 149, 217, 225
- sexual activity 238–42, 252, 255, 258  
 non-consensual *see* non-consensual  
 sexual intercourse
- sexual contacts *see* household and close  
 contacts
- sexual partners 216–17, 223, 224–5,  
 230, 238–40, 259
- sexually transmitted infections (STIs)  
 217, 245, 259
- sharps containers 664
- shingles *see* zoster

- SHIVERS 277–8, 677
- shock 335, 539
- siblings *see* household and close contacts
- sickle cell disease 121, 138, 177, 417
- sinusitis 172, 175, 310, 407
- skin conditions, infected 527
- skin disorders 529
- skin preparation 61, 69
- skin scars 556, 564
- skin tests 654
- see also* tuberculin skin testing
- sleep, decreased or increased 428
- sleep changes 75
- sleep disorders 565
- sleepiness 448
- difficulty to rouse 335
- smoking 213, 240, 337, 426
- sneezing 78
- socioeconomic status 156, 242, 455, 457
- high-income countries 144, 156–7, 160–1, 241, 310, 337, 376, 418, 441, 455, 462–3, 521, 538
- low-income groups and countries 275, 311, 376, 407, 455, 463, 499, 521–2
- see also* household deprivation
- sodium 647
- sodium bicarbonate 540
- sodium borate 212
- sodium chloride 159, 175, 190, 212, 282, 341–2, 414, 540, 567
- sodium citrate 460
- sodium glutamate 520
- sodium hydroxide 159, 460
- sodium phosphate 190, 341, 540
- sodium phosphate dibasic 282, 567
- sodium phosphate monobasic monohydrate 460
- solid organ transplants *see* organ transplants
- soothing measures 76–7
- sorbitol 29, 314, 540–1
- sore throat 273
- soreness at injection site 75, 197
- Southern Hemisphere Influenza, Vaccine Effectiveness, Research and Surveillance 277–8, 677
- spacing of doses 53, 599
- concurrent administration 54, 72, 89
- different vaccines 53, 176, 215, 253, 316, 346, 351–2, 365, 382, 430, 445, 464, 484, 503, 543, 568–9, 571
- inactivated vaccines 53, 419, 427, 445, 653
- live vaccines 53, 72, 89, 316, 365, 464, 484, 543
- possible reactions 289–90, 296, 419, 427, 523
- same vaccine 53
- vaccines and blood or IG 161, 382, 467–8, 503, 523, 653, 656
- dose intervals 73, 89, 163, 222–3, 383–4, 505
- between vaccines and blood or IG 49, 321, 467–8, 651–3, 652–3, 656
- influenza vaccines 289–90, 296
- pneumococcal vaccines 419, 427, 602
- polio vaccines 445, 446
- rotavirus vaccines 464, 466, 467–8, 523, 601
- same vaccine 49
- spasms 386, 498
- special groups 6, 7–11, 56–8, 111, 602, 605, 612
- asplenic *see* asplenic children and adults
- immune-deficient *see*
- immunosuppression
- other conditions 121
- pregnant women *see under* pregnancy
- preterm infants *see* preterm infants
- splenectomy *see* asplenic children and adults
- transplants *see* transplants
- vaccines
- BCG vaccine 120, 121, 123, 145, 523–6
- diphtheria vaccines 130–1, 164–5
- hepatitis A vaccines 56, 117–18, 133
- hepatitis B vaccines 6, 56, 115, 117–18, 130–3, 137, 145, 218–21, 222–3
- Hib vaccines 56, 124, 131–3, 138–9, 141–2, 177–9
- HPV vaccines 118, 133, 136–7, 139–40, 254
- inactivated vaccines 112–13, 123, 124
- influenza vaccines 112–13, 115, 119, 121, 123–7, 130, 132–7, 139–43, 291, 292–4
- live vaccines 93–4, 116, 119–20, 122, 123, 126, 130, 132
- meningococcal vaccines 123, 125, 131–43, 346–8



- MMR vaccines 111–12, 114, 117–18, 123, 130–1, 133, 135–8, 319–20, 366–7, 488–9
- pertussis vaccines 113, 115, 130–1, 384–5
- pneumococcal vaccines 6, 116, 123, 125, 130–42, 143, 421–5
- polio vaccines 130–1, 446–7
- rotavirus vaccines 91, 114, 116, 120, 123, 133, 466–7
- tetanus vaccines 118, 124, 130–1, 133, 385, 508–9
- varicella vaccines 112, 117, 119–21, 123–4, 126, 130–3, 135–7, 139–40, 142, 145, 544–6, 558
- see also* high-risk groups; *specific vaccines*
- sphincter control, poor 556
- spillages 664–5
- splenectomy *see* asplenic children and adults
- spontaneous abortions 362
- stabilisers 29, 647–8
- Starship Clinical Guidelines for Needle-stick Injuries* 666
- Starship Hospital (Auckland) 130–2, 138, 539
- sterility 362
- steroids 11, 143, 321, 547
- stiffness 498
- stiffness, muscle 655
- stiffness of the neck and back 440
- stillbirths 113, 286, 292, 311
- stools
  - clay coloured 206
  - pink- or red-coloured jelly-like 470
- Strategic Advisory Group of Experts on Immunization 31
- streptomycin 443
- stridor 78–9
- strokes 537
- students 57, 147–8, 150, 242, 318, 336, 347–8, 353, 363, 546
- sub-acute sclerosing panencephalitis 311
- subcutaneous (SC) injections 62, 63, 65, 655
- substernal pressure 78
- sub-unit vaccines 25, 26–8, 53, 123, 283
- see also* diphtheria vaccines; hepatitis B vaccines; Hib vaccines; HPV vaccines; influenza vaccines; meningococcal vaccines; pertussis vaccines; pneumococcal vaccines; tetanus vaccines
- succinic acid 414
- sucrose 29, 175, 342, 460, 540, 567, 648, 656
- SUDI (sudden unexplained death in infancy) 100, 386
- sulfamethoxazole 392
- surfactants 29
- Suspected Medicine Adverse Reaction Search (SMARS)* 31
- swallowing food, difficulties 498
- swelling at injection site 75, 180, 197, 228, 257, 297, 322, 351, 387, 429, 448, 511, 548
- swelling of limbs 388
- swelling of salivary glands 322, 362
- syncope *see* fainting
- Synflorix vaccine *see* PCV10 vaccine; pneumococcal vaccines
- syringes *see under* injections
- systemic reactions 166, 351, 387, 655
  - influenza vaccines 284, 296–7
  - pneumococcal vaccines 420, 427, 429
- tachycardia 79, 335
- tattooists and tattooing 149, 157, 224
- TB 10, 91, 121, 144–5, 547, 570
  - bacteriology 516
  - clinical features 516–17, 517
  - epidemiology 518–19
  - high-incidence countries 524, 667, 668–71
  - key information 515–16
  - latent phase 516–17, 520–1, 530
  - multi-drug resistant 519
  - public health measures 530
  - risk of transmission 519
- TB vaccine *see* BCG vaccine
- T-cell immune deficiency syndrome 116, 122, 124, 125, 547
- Td (adult tetanus diphtheria) vaccine 5, 159, 162–3, 501, 511
  - boosters 11, 162–5, 167
  - contraindications and precautions 509

- dosage and administration 161, 384, 503, 505
- expected responses and adverse events 75, 387, 510–11
- history of schedule 578
- recommended immunisation schedule 5, 57, 162–3, 503–5, 503 special groups 124, 509
- transport, storage and handling 502
- Tdap (tetanus, adult diphtheria and acellular pertussis) vaccine 159, 167, 380, 388, 395, 501
  - boosters 161–4, 383, 503, 601, 604
  - catch-up programmes 601, 604, 610
  - contraindications and precautions 395, 509
  - dosage and administration 161, 165, 382, 384, 503, 505
  - efficacy and effectiveness 382
  - expected responses and adverse events 75, 387, 510
  - history of schedule 579
  - not funded but recommended 57, 385
  - recommended immunisation schedule 5, 162–5, 383, 385, 501, 503–5, 503, 612
  - special groups 118, 131, 133, 385, 509
- Tdap-IPV (tetanus, adult diphtheria, acellular pertussis, inactivated polio) vaccine 159, 380, 443, 501
  - see also* tetanus vaccines
- teachers 147
- teenagers *see* adolescents
- temperature monitoring 41, 658
- tenderness at injection site 228, 351, 655
- tenderness of salivary glands 362
- tenofovir 213, 220
- terminal complement components deficiency (C5-9) 336
- termination of pregnancy 489, 493
- tetanus
  - bacteriology 498
  - clinical features 498–9
  - epidemiology 499–500
  - incubation period 498
  - key information 497
  - public health measures 511
- tetanus immunoglobulin 506–7, 646–7, 652
- tetanus toxoid (TT) 27
- tetanus vaccines 20, 26, 500–1
  - boosters 11, 57, 130, 161–5, 167, 502–5, 507, 509, 604, 612
  - contraindications and precautions 509–10
  - dosage and administration 382, 384, 503, 505
  - efficacy and effectiveness 101, 382, 501–2
  - expected responses and adverse events 34, 75, 510–11
  - history of schedule 575, 578, 595–6
  - recommended immunisation schedule 57, 162–5, 385, 503–5, 503, 612
  - single-antigen vaccine 500, 502
  - special groups *see under* special groups
  - transport, storage and handling 502
  - variations from vaccine data sheets 511
- thalassaemia 138
- thiomersal 29, 460
- thrombocytopenia 51, 65, 229, 655
  - MMR 34, 311, 321, 323, 480, 490
- thrombosis 548
- thyroiditis 362
- TIG 506–7, 646–7, 652
- timing of doses *see* spacing of doses
- tissue necrosis 81
- tobacco 242, 244
- topical anaesthetics 77
- toxic chemicals, viruses and cells 103
- toxoid vaccines 26, 27, 158–9
- tracking 59, 61, 67, 658
- training of vaccinators 65, 625, 630–6
- transplants 7–8, 10, 56–8, 116, 119, 193, 253–4, 291, 544
  - bone marrow *see* haematopoietic stem cell transplant
  - HSCT *see* haematopoietic stem cell transplants
  - kidney *see* kidney transplants
  - liver *see* liver transplants
  - organ *see* organ transplants
- transport of vaccines 40, 664
- travellers *see* overseas travel
- trimethoprim 392
- trivalent inactivated vaccines (TIV) 283
  - see also* influenza vaccines
- trometamol 175, 190, 342

- tropical countries 145, 274, 294, 441, 538, 546
- Trumenba vaccine 343  
*see also* meningococcal vaccines
- tuberculin skin testing 145, 321, 516, 522–6, 529–30, 548
- tuberculin syringes 63, 81
- Tuberculosis in New Zealand: Annual Report* 518
- tubular necrosis 155
- tumours 527
- Twinrix/Twinrix Junior vaccine *see* HAV-HepB vaccine
- typhoid vaccines 190
- ulcerations, shallow 528
- ulcers 529
- umbilical stump infection 499
- unfunded *see* not funded vaccines
- unimmunised children and adults 251, 286–8, 344, 369, 377, 500, 643  
 catch-up programmes 54–5, 57, 420, 445–6, 504, 541–2, 545, 600, 602, 605  
 outbreaks 156, 173, 299, 312, 462  
 public health measures 181, 199, 324–5  
*see also* exclusion of contacts
- unsettledness 75
- unvaccinated adults and children *see* unimmunised children and adults
- upper respiratory tract infections *see* respiratory tract infections
- urea 540, 567
- urticaria 78, 180, 655
- US Advisory Committee on Immunization Practices (ACIP) 252, 283, 343
- vaccination  
 history *see* immunisation history  
 questions and concerns *see* questions and concerns  
*see also* immunisation
- Vaccinator Training Certificate (VTC) 631
- Vaccinator Training Course Standards* 631, 635–6
- Vaccinator Update Course Standards* 633–5
- vaccinators 65, 68–9  
 AEFI reporting process 33
- authorisation of *see* authorisation of vaccinators
- authorised *see* authorised vaccinators
- BCG endorsed *see* BCG endorsed vaccinators
- indemnity insurance 84
- pharmacist *see* pharmacist vaccinators
- role and responsibility 40, 111, 296, 485, 529, 665  
 adherence to standards *see* Immunisation standards for vaccinators
- administration of vaccines 40, 41, 48, 60, 522
- anaphylaxis 77–8, 80
- catch-up programmes 54, 599
- documentation and records 83–4, 85, 620–3, 643–4  
 regular checks of updates 3, 7
- training 65, 625, 630–6
- vaccine components 28–30, 103, 197, 427
- adjuvants *see* adjuvants
- preservatives *see* preservatives
- reactions to  
 allergic reactions 228, 467  
 anaphylaxis 51, 90, 94, 165, 180, 256, 294, 320–2, 350–1, 367, 385, 395, 447, 489, 547  
 hypersensitivity 509, 527, 547, 569
- residuals 30
- stabilisers 29, 647–8
- surfactants/emulsifiers 29
- vaccine contraindications *see* contraindications and precautions
- vaccine failure 73, 105  
 hepatitis B vaccines 226–8, 227  
 meningococcal vaccines 342, 350  
 MMR vaccines 315–16, 328, 364, 485
- vaccine hesitancy 44–5, 95
- Vaccine Ingredients* 103
- The Vaccine Page 676
- vaccine presentation 657
- vaccine production *see* manufacturers
- vaccine safety *see* safety
- vaccine scheduling *see* administration of vaccines; spacing of doses
- vaccine storage and handling  
 cold chain 40, 40

- specific vaccines 176, 214, 345, 444, 521–2, 542
  - MMR vaccines 316, 364, 484
  - pertussis vaccines 161, 382, 502
- temperature monitoring and performance 41, 658
- vaccine refrigerator 41
- vaccine transportation 40, 664
- vaccine-associated paralytic poliomyelitis (VAPP) 442, 446
- vaccine-related febrile seizures 94
- vaccine-related pneumonitis 321, 367, 489
- vaccines 16–21
  - administration *see* administration of vaccines
  - classification of 24, 25
  - inactivated *see* inactivated vaccines
  - killed 25
  - live vaccines *see* live vaccines
  - sub-unit *see* sub-unit vaccines, ingredients *see* vaccine components
- varicella vaccines (VV) 540–1
  - catch-up programmes 602, 605, 608–10
  - contraindications and precautions 125, 547–8, 552
  - dosage and administration 543
  - efficacy and effectiveness 541–2, 545
  - expected responses and adverse events 75, 548–50, 553
  - history of schedule 580, 597
  - not funded but recommended *see under* not funded vaccines
  - recommended immunisation schedule 5, 58, 543–5, 544
  - risk of transmission 95, 549
  - special groups *see under* special groups
  - transport, storage and handling 542–3
  - vaccines
    - monovalent varicella vaccine 540
    - quadrivalent varicella vaccine 540–1
  - variations from vaccine data sheets 558
- varicella zoster immunoglobulin *see* ZIG
- varicella zoster virus (VZV) 133, 564, 569
  - clinical features 536–7
  - epidemiology 537–9
  - incubation period 536
  - key information 535–6
  - latent phase *see* zoster
  - public health measures 550–7
  - virology 536
- Varilrix vaccine (VV) 4, 5, 540, 543, 545, 558
  - special groups 117, 119, 135–7, 142 *see also* varicella vaccines
- Varivax vaccine 142, 540
  - see also* varicella vaccines
- vasovagal syncope *see* fainting
- vastus lateralis injection sites 62–4, 66, 67, 69–73, 70, 82
- Vaxigrip vaccine 282
  - see also* influenza vaccines
- ventricular failure 81
- veterinarians, veterinary students and nurses 148
- vials 657–60, 663–4
- virological surveillance 677
- vitamin A deficiency 311
- vitamin K injections 219
- Vivaxim (hepatitis A and typhoid vaccine) 190, 196
- vomiting 75, 78–9, 206, 273, 335, 374–5, 387, 448, 655
  - rotavirus 454–5, 464, 469, 470, 471
- von Willebrand disease 655
- VV *see* varicella vaccines
- warmth 78
- weakness 498
- websites 626
  - American Academy of Pediatrics 676
  - Association of Paediatric Anaesthetists of Great Britain and Ireland 93
  - Australian Government 46
  - Centers for Disease Control and Prevention 146, 675, 678, 679
  - ESR 275, 408, 449, 456, 518, 674, 677
  - Fitfortravel 679
  - Health and Disability Commissioner 43, 47, 616
  - Health Promotion Agency 675
  - Health Protection Agency 326
  - HealthEd 45, 46, 218, 525, 644, 674
  - IMAC 46, 97, 507, 674

- Immunization Action Coalition 676  
 Influenza Communication Campaign 281  
 Institute for Vaccine Safety 676  
 Kidshealth 675  
 local immunisation coordinator 46  
 Medsafe 30, 31, 46, 62, 65, 464, 662, 674, 677  
 Ministry of Health 3, 12–13, 24, 85, 92, 144, 449, 530, 633, 673, 679  
 National Centre for Immunisation Research & Surveillance 676  
 National Influenza Specialist Group 677  
 National Measles Laboratory 324  
 New Zealand Resuscitation Council 638  
 Nursing Council of NZ 43  
 NZBS 648–9  
 Pandemic planning and response 677  
 PHARMAC 3, 673–4  
 Privacy Commissioner 44  
 Starship Hospital 130–2, 138  
 The Vaccine Page 676  
 WHO 144, 146, 347, 675, 678, 679  
*see also* blogs  
 weight loss 375, 517  
*Well Child Tamariki Ora My Health Book* 84, 644  
 Well Child Tamariki Ora services 12, 144, 621, 623  
 WHO 24, 30–1, 252, 407, 470, 675  
 Addressing Vaccine Hesitancy 44  
 Expanded Programme of Immunization 522–3  
 Global Advisory Committee on Vaccine Safety 31, 103, 257  
 global eradication 104  
   Global Polio Eradication Initiative 441–2  
   measles and rubella 99, 104  
*Global Vaccine Action Plan 2011–2020* 312  
 influenza 272, 283  
   Collaborating Centre for Reference and Research on Influenza 678  
   FluNet 678  
   Global Influenza Programme 275, 678  
 international travel and health 679  
 Measles Regional Verification Commission 312  
 Strategic Advisory Group of Experts on Immunization 31, 59  
 tuberculosis 518, 521  
 World Health Assembly 312  
*see also* *under* websites  
 whole-cell pertussis vaccines 380, 381, 386  
   *see also* pertussis vaccines  
 whooping cough *see* pertussis  
 wild-type virus 227, 441–3  
   MMR 311, 481, 484  
   rotavirus 456, 463, 467  
   varicella zoster virus 538, 542, 549  
   zoster 538, 549, 565, 570  
 Willebrand disease, von 655  
 Wiskott-Aldrich syndrome 125  
 women  
   childbearing aged women *see* childbearing aged women  
   HPV *see* HPV vaccines  
 work, exclusion 369, 394, 491, 547, 553–4  
 World Health Organization *see* WHO  
 wound management 10, 164, 385, 498, 505–11, 507, 653, 665  
 yeast 212, 228, 247, 256  
 yellow fever vaccines 656  
 young children 28, 100–1, 276–7, 325, 336, 409, 520  
   catch-up programmes 90, 600–2, 603, 608, 609  
   injections 62, 69–71, 70  
   recommended immunisation schedule 134–5, 162, 178, 422–3  
   influenza vaccines 285, 291, 294  
   meningococcal vaccines 340, 344–6  
   MMR vaccines 317, 366  
 youth service workers 147  
 ZIG 536, 549, 550–2, 552, 554–5, 557, 646, 652  
 zoo staff 149, 193  
 Zostavax vaccine *see* zoster vaccine  
 zoster 102, 536, 537–8, 549, 569  
   clinical features 564–5  
   epidemiology 565–6, 566  
   key information 563  
   virology 564

zoster immunoglobulin *see* ZIG  
zoster vaccine 430, 567  
    autoimmune conditions, and 102  
    boosters 568  
    contraindications and precautions  
        569–70  
    dosage and administration 420,  
        568–9  
    efficacy and effectiveness 567–8  
    expected responses and adverse  
        events 570  
    recommended immunisation  
        schedule 569  
    transport, storage and handling 568  
    variations from vaccine data sheets  
        571